{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:40:40Z","timestamp":1790044840116,"version":"4.0.1"},"reference-count":287,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13346-025-01799-8","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:24:15Z","timestamp":1738146255000},"page":"855-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nanotechnology in Parkinson\u2019s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes"],"prefix":"10.1007","volume":"16","author":[{"given":"Irfan","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Asif","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-1735","authenticated-orcid":false,"given":"Nazeer","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan Jalees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"1","key":"1799_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics15010013","volume":"15","author":"N Paccione","year":"2023","unstructured":"Paccione N, Rahmani M, Barcia E, Negro S. Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems. Pharmaceutics. 2023;15(1):1\u201333. https:\/\/doi.org\/10.3390\/pharmaceutics15010013.","journal-title":"Pharmaceutics"},{"key":"1799_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.parkreldis.2019.01.010","volume":"63","author":"M Ruiz-Lopez","year":"2019","unstructured":"Ruiz-Lopez M, et al. Diagnostic delay in Parkinson\u2019s disease caused by PRKN mutations. Park Relat Disord. 2019;63:217\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.01.010.","journal-title":"Park Relat Disord"},{"issue":"10423","key":"1799_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2.","journal-title":"Lancet"},{"issue":"1","key":"1799_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/PTR.6523","volume":"34","author":"E Anis","year":"2020","unstructured":"Anis E, et al. Ferulic acid reinstates mitochondrial dynamics through PGC1\u03b1 expression modulation in 6-hydroxydopamine lesioned rats. Phytother Res. 2020;34(1):214\u201326. https:\/\/doi.org\/10.1002\/PTR.6523.","journal-title":"Phytother Res"},{"issue":"1","key":"1799_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JPD-212922","volume":"12","author":"BR De Miranda","year":"2022","unstructured":"De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson\u2019s Disease: An Environmental Agenda. J Parkinsons Dis. 2022;12(1):45\u201368. https:\/\/doi.org\/10.3233\/JPD-212922.","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"1799_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","volume":"23","author":"AD Kulkarni","year":"2015","unstructured":"Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: A mini review. J Drug Target. 2015;23(9):775\u201388. https:\/\/doi.org\/10.3109\/1061186X.2015.1020809.","journal-title":"J Drug Target"},{"issue":"8","key":"1799_CR7","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3233\/JPD-223363","volume":"12","author":"C Coleman","year":"2022","unstructured":"Coleman C, Martin I. Unraveling Parkinson\u2019s Disease Neurodegeneration: Does Aging Hold the Clues? J Parkinsons Dis. 2022;12(8):2321\u201338. https:\/\/doi.org\/10.3233\/JPD-223363.","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"1799_CR8","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","volume":"64","author":"G Levy","year":"2007","unstructured":"Levy G. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64(9):1242\u20136. https:\/\/doi.org\/10.1001\/archneur.64.9.1242.","journal-title":"Arch Neurol"},{"issue":"5","key":"1799_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-023-03553-8","volume":"13","author":"H Adam","year":"2023","unstructured":"Adam H, et al. An update on pathogenesis and clinical scenario for Parkinson\u2019s disease: diagnosis and treatment. 3 Biotech. 2023;13(5):1\u201318. https:\/\/doi.org\/10.1007\/s13205-023-03553-8.","journal-title":"3 Biotech"},{"issue":"1","key":"1799_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-202279","volume":"11","author":"RJ Smeyne","year":"2021","unstructured":"Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and risk of Parkinson\u2019s disease. J Parkinsons Dis. 2021;11(1):31\u201343. https:\/\/doi.org\/10.3233\/JPD-202279.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"1799_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ANA.26852","volume":"95","author":"A Reynoso","year":"2024","unstructured":"Reynoso A, et al. Gene\u2013Environment Interactions for Parkinson\u2019s Disease. Ann Neurol. 2024;95(4):677\u201387. https:\/\/doi.org\/10.1002\/ANA.26852.","journal-title":"Ann Neurol"},{"issue":"3","key":"1799_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","volume":"68","author":"M Funayama","year":"2023","unstructured":"Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson\u2019s disease: Contributions and global trends. J Hum Genet. 2023;68(3):125\u201330. https:\/\/doi.org\/10.1038\/s10038-022-01058-5.","journal-title":"J Hum Genet"},{"issue":"10","key":"1799_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","volume":"91","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, et al. Parkinson\u2019s disease determinants, prediction and gene-environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry. 2020;91(10):1046\u201354. https:\/\/doi.org\/10.1136\/jnnp-2020-323646.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1799_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D. The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol. 2022;21(1):89\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(21)00330-6.","journal-title":"Lancet Neurol"},{"key":"1799_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnana.2018.00113","volume":"12","author":"NLG Del Rey","year":"2018","unstructured":"Del Rey NLG, et al. Advances in parkinson\u2019s disease: 200 years later. Front Neuroanat. 2018;12:1\u201314. https:\/\/doi.org\/10.3389\/fnana.2018.00113.","journal-title":"Front Neuroanat"},{"issue":"4","key":"1799_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jnen\/63.4.329","volume":"63","author":"TG Beach","year":"2004","unstructured":"Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia Nigra Marinesco Bodies Are Associated with Decreased Striatal Expression of Dopaminergic Markers. J Neuropathol Exp Neurol. 2004;63(4):329\u201337. https:\/\/doi.org\/10.1093\/jnen\/63.4.329.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1799_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.arr.2024.102208","volume":"94","author":"R Soni","year":"2024","unstructured":"Soni R, Mathur K, Shah J. An update on new-age potential biomarkers for Parkinson\u2019s disease. Ageing Res Rev. 2024;94:1568\u2013637. https:\/\/doi.org\/10.1016\/j.arr.2024.102208.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1799_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-019-0165-9","volume":"8","author":"SYY Pang","year":"2019","unstructured":"Pang SYY, et al. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson\u2019s disease. Transl Neurodegener. 2019;8(1):1\u201311. https:\/\/doi.org\/10.1186\/s40035-019-0165-9.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1799_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","volume":"25","author":"Y Chu","year":"2007","unstructured":"Chu Y, Kordower JH. Age-associated increases of \u03b1-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson\u2019s disease? Neurobiol Dis. 2007;25(1):134\u201349. https:\/\/doi.org\/10.1016\/j.nbd.2006.08.021.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1799_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1523\/JNEUROSCI.4308-05.2006","volume":"26","author":"LJ Martin","year":"2006","unstructured":"Martin LJ, et al. Parkinson\u2019s disease \u03b1-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26(1):41\u201350. https:\/\/doi.org\/10.1523\/JNEUROSCI.4308-05.2006.","journal-title":"J Neurosci"},{"issue":"2","key":"1799_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020283","volume":"10","author":"DA Madsen","year":"2021","unstructured":"Madsen DA, Schmidt SI, Blaabjerg M, Meyer M. Interaction between parkin and \u03b1-synuclein in park2-mediated parkinson\u2019s disease. Cells. 2021;10(2):1\u201330. https:\/\/doi.org\/10.3390\/cells10020283.","journal-title":"Cells"},{"issue":"9","key":"1799_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson\u2019s disease dementia: Convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14(9):626\u201336. https:\/\/doi.org\/10.1038\/nrn3549.","journal-title":"Nat Rev Neurosci"},{"key":"1799_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mito.2019.09.010","volume":"50","author":"L Rani","year":"2020","unstructured":"Rani L, Mondal AC. Emerging concepts of mitochondrial dysfunction in Parkinson\u2019s disease progression: Pathogenic and therapeutic implications. Mitochondrion. 2020;50:25\u201334. https:\/\/doi.org\/10.1016\/j.mito.2019.09.010.","journal-title":"Mitochondrion"},{"key":"1799_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2010.00034","volume":"2","author":"A Navarro","year":"2010","unstructured":"Navarro A, Boveris A. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson\u2019s disease. Front Aging Neurosci. 2010;2:1\u201311. https:\/\/doi.org\/10.3389\/fnagi.2010.00034.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1799_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ageing\/afp223","volume":"39","author":"JV Hindle","year":"2010","unstructured":"Hindle JV. Ageing, neurodegeneration and Parkinson\u2019s disease. Age Ageing. 2010;39(2):156\u201361. https:\/\/doi.org\/10.1093\/ageing\/afp223.","journal-title":"Age Ageing"},{"issue":"10","key":"1799_CR26","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1021\/acsptsci.4c00151","volume":"7","author":"S Choudhary","year":"2024","unstructured":"Choudhary S, et al. Crocetin Delays Brain and Body Aging by Increasing Cellular Energy Levels in Aged C57BL\/6J Mice. ACS Pharmacol Transl Sci. 2024;7(10):3017\u201333. https:\/\/doi.org\/10.1021\/acsptsci.4c00151.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"1799_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","volume":"14","author":"A Reeve","year":"2014","unstructured":"Reeve A, Simcox E, Turnbull D. Ageing and Parkinson\u2019s disease: Why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14(1):19\u201330. https:\/\/doi.org\/10.1016\/j.arr.2014.01.004.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"1799_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/J.TIBS.2020.11.007\/ASSET\/DBF1B28B-0A86-4B9F-A935-6DD32FE6A7AC\/MAIN.ASSETS\/GR3.SML","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial Dysfunction and Mitophagy in Parkinson\u2019s Disease: From Mechanism to Therapy. Trends Biochem Sci. 2021;46(4):329\u201343. https:\/\/doi.org\/10.1016\/J.TIBS.2020.11.007\/ASSET\/DBF1B28B-0A86-4B9F-A935-6DD32FE6A7AC\/MAIN.ASSETS\/GR3.SML.","journal-title":"Trends Biochem Sci"},{"issue":"9","key":"1799_CR29","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/archneurol.2009.195","volume":"66","author":"CM Tanner","year":"2009","unstructured":"Tanner CM, et al. Occupation and Risk of Parkinsonism. Arch Neurol. 2009;66(9):1106\u201313. https:\/\/doi.org\/10.1001\/archneurol.2009.195.","journal-title":"Arch Neurol"},{"issue":"17013","key":"1799_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3(17013):1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13.","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"1799_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1289\/ehp.1002839","volume":"119","author":"CM Tanner","year":"2011","unstructured":"Tanner CM, et al. Rotenone, paraquat, and Parkinson\u2019s disease. Environ Health Perspect. 2011;119(6):866\u201372. https:\/\/doi.org\/10.1289\/ehp.1002839.","journal-title":"Environ Health Perspect"},{"issue":"13","key":"1799_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/mds.25143","volume":"27","author":"F Fang","year":"2012","unstructured":"Fang F, Chen H, Feldman AL, Kamel F, Ye W, Wirdefeldt K. Head injury and Parkinson\u2019s disease: A population-based study. Mov Disord. 2012;27(13):1632\u20135. https:\/\/doi.org\/10.1002\/mds.25143.","journal-title":"Mov Disord"},{"issue":"7685","key":"1799_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/bmj.a2494","volume":"338","author":"K Rugbjerg","year":"2009","unstructured":"Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson\u2019s disease after hospital contact for head injury: Population based case-control study. BMJ. 2009;338(7685):34\u20136. https:\/\/doi.org\/10.1136\/bmj.a2494.","journal-title":"BMJ"},{"issue":"11","key":"1799_CR34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1212\/wnl.0000000000001362","volume":"84","author":"L Kenborg","year":"2015","unstructured":"Kenborg L, et al. Head injury and risk for Parkinson disease. Neurology. 2015;84(11):1098\u2013103. https:\/\/doi.org\/10.1212\/wnl.0000000000001362.","journal-title":"Neurology"},{"issue":"1","key":"1799_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-171238","volume":"8","author":"H Chen","year":"2018","unstructured":"Chen H. The changing landscape of Parkinson epidemiologic research. J Parkinsons Dis. 2018;8(1):1\u201312. https:\/\/doi.org\/10.3233\/JPD-171238.","journal-title":"J Parkinsons Dis"},{"key":"1799_CR36","doi-asserted-by":"publisher","unstructured":"MH Polymeropoulos et al., \u201cMutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease,\u201d. Science (80-. )., 276, 5321, 2045\u20132047, 1997, https:\/\/doi.org\/10.1126\/science.276.5321.2045","DOI":"10.1126\/science.276.5321.2045"},{"key":"1799_CR37","doi-asserted-by":"publisher","unstructured":"M. Goedert, \u201cAlzheimer\u2019s and Parkinson\u2019s diseases: The prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein,\u201d. Science (80-. )., 349, 6248, 61\u201369, 2015, https:\/\/doi.org\/10.1126\/science.1255555","DOI":"10.1126\/science.1255555"},{"issue":"7","key":"1799_CR38","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/GENES12071006","volume":"12","author":"JO Day","year":"2021","unstructured":"Day JO, Mullin S. The genetics of parkinson\u2019s disease and implications for clinical practice. Genes (Basel). 2021;12(7):1006. https:\/\/doi.org\/10.3390\/GENES12071006.","journal-title":"Genes (Basel)"},{"key":"1799_CR39","doi-asserted-by":"publisher","unstructured":"A. B. Singleton et al., \u201c\u03b1-Synuclein Locus Triplication Causes Parkinson\u2019s Disease,\u201d. Science (80-. )., 302, 5646, 841, 2003, https:\/\/doi.org\/10.1126\/science.1090278","DOI":"10.1126\/science.1090278"},{"key":"1799_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2017.00177","volume":"8","author":"MP Helley","year":"2017","unstructured":"Helley MP, Pinnell J, Sportelli C, Tieu K. Mitochondria: A common target for genetic mutations and environmental toxicants in Parkinson\u2019s disease. Front Genet. 2017;8:1\u201324. https:\/\/doi.org\/10.3389\/fgene.2017.00177.","journal-title":"Front Genet."},{"issue":"3","key":"1799_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.10113","volume":"51","author":"M Funayama","year":"2002","unstructured":"Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson\u2019s Disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002;51(3):296\u2013301. https:\/\/doi.org\/10.1002\/ana.10113.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"1799_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jnc.13593","volume":"139","author":"DG Hernandez","year":"2016","unstructured":"Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem. 2016;139(Suppl 1):59\u201374. https:\/\/doi.org\/10.1111\/jnc.13593.","journal-title":"J Neurochem"},{"issue":"3","key":"1799_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1242\/JCS.158196\/259202\/AM\/LRRK2-FUNCTIONS-IN-SYNAPTIC-VESICLE-ENDOCYTOSIS","volume":"128","author":"AM Arranz","year":"2015","unstructured":"Arranz AM, et al. LRRK2 functions in synaptic vesicle endocytosis through a kinasedependent mechanism. J Cell Sci. 2015;128(3):541\u201352. https:\/\/doi.org\/10.1242\/JCS.158196\/259202\/AM\/LRRK2-FUNCTIONS-IN-SYNAPTIC-VESICLE-ENDOCYTOSIS.","journal-title":"J Cell Sci"},{"issue":"9","key":"1799_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","volume":"89","author":"O Neudorfer","year":"1996","unstructured":"Neudorfer O, et al. Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease. QJM An Int J Med. 1996;89(9):691\u20134. https:\/\/doi.org\/10.1093\/qjmed\/89.9.691.","journal-title":"QJM An Int J Med"},{"issue":"3","key":"1799_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bcmd.2006.02.004","volume":"36","author":"A Halperin","year":"2006","unstructured":"Halperin A, Elstein D, Zimran A. \u201cIncreased incidence of Parkinson disease among relatives of patients with Gaucher disease\u201d, Blood Cells. Mol Dis. 2006;36(3):426\u20138. https:\/\/doi.org\/10.1016\/j.bcmd.2006.02.004.","journal-title":"Mol Dis"},{"issue":"3","key":"1799_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82(3):192\u2013207. https:\/\/doi.org\/10.1016\/j.ymgme.2004.04.011.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1799_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/07853890.2013.849003","volume":"45","author":"MS Beavan","year":"2013","unstructured":"Beavan MS, Schapira AHV. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med. 2013;45(8):511\u201321. https:\/\/doi.org\/10.3109\/07853890.2013.849003.","journal-title":"Ann Med"},{"key":"1799_CR48","doi-asserted-by":"publisher","unstructured":"L. Pan, L. Meng, M. He, and Z. Zhang, \u201cTau in the Pathophysiology of Parkinson\u2019s Disease,\u201d. J Mol Neurosci. 2021 7111, 71, 11, 2179\u20132191, 2021, https:\/\/doi.org\/10.1007\/S12031-020-01776-5","DOI":"10.1007\/S12031-020-01776-5"},{"issue":"2","key":"1799_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15548627.2019.1603545","volume":"16","author":"PWL Ho","year":"2020","unstructured":"Ho PWL, et al. Age-dependent accumulation of oligomeric SNCA\/\u03b1-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy. 2020;16(2):347\u201370. https:\/\/doi.org\/10.1080\/15548627.2019.1603545.","journal-title":"Autophagy"},{"issue":"5","key":"1799_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.parkreldis.2015.02.010","volume":"21","author":"CH Lin","year":"2015","unstructured":"Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson\u2019s disease. Park Relat Disord. 2015;21(5):431\u201343. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.010.","journal-title":"Park Relat Disord"},{"issue":"1","key":"1799_CR51","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/0022146515594631.Marriage","volume":"176","author":"R Micha","year":"2017","unstructured":"Micha R. \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access. Physiol Behav. 2017;176(1):100\u20136. https:\/\/doi.org\/10.1177\/0022146515594631.Marriage.","journal-title":"Physiol Behav"},{"key":"1799_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2022.939855","volume":"16","author":"L La Barbera","year":"2022","unstructured":"La Barbera L, Mauri E, D\u2019Amelio M, Gori M. Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer\u2019s disease: Current trends and future perspectives. Front Neurosci. 2022;16:1\u201332. https:\/\/doi.org\/10.3389\/fnins.2022.939855.","journal-title":"Front Neurosci"},{"issue":"1","key":"1799_CR53","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.33549\/physiolres.934324","volume":"68","author":"M L\u2019upt\u00e1k","year":"2019","unstructured":"L\u2019upt\u00e1k M, Hroudov\u00e1 J. Important role of Mitochondria and the effect of mood stabilizers on mitochondrial function. Physiol Res. 2019;68(1):s3\u201315. https:\/\/doi.org\/10.33549\/physiolres.934324.","journal-title":"Physiol Res"},{"issue":"21","key":"1799_CR54","doi-asserted-by":"publisher","first-page":"R1177","DOI":"10.1016\/j.cub.2017.09.015","volume":"27","author":"AJ Roger","year":"2017","unstructured":"Roger AJ, Mu\u00f1oz-G\u00f3mez SA, Kamikawa R. The Origin and Diversification of Mitochondria. Curr Biol. 2017;27(21):R1177\u201392. https:\/\/doi.org\/10.1016\/j.cub.2017.09.015.","journal-title":"Curr Biol"},{"key":"1799_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1155\/2020\/8837893","volume":"2020","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, et al. Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment. Oxid Med Cell Longev. 2020;2020:18. https:\/\/doi.org\/10.1155\/2020\/8837893.","journal-title":"Oxid Med Cell Longev"},{"issue":"11","key":"1799_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ncpneuro0924","volume":"4","author":"C Henchcliffe","year":"2008","unstructured":"Henchcliffe C, Beal FM. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600\u20139. https:\/\/doi.org\/10.1038\/ncpneuro0924.","journal-title":"Nat Clin Pract Neurol"},{"key":"1799_CR57","doi-asserted-by":"publisher","first-page":"108698","DOI":"10.1016\/j.abb.2020.108698","volume":"702","author":"J Johnson","year":"2021","unstructured":"Johnson J, et al. Mitochondrial dysfunction in the development and progression of neurodegenerative diseases. Arch Biochem Biophys. 2021;702:108698. https:\/\/doi.org\/10.1016\/j.abb.2020.108698.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"1799_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00441-017-2768-8","volume":"373","author":"SB Larsen","year":"2018","unstructured":"Larsen SB, Hanss Z, Kr\u00fcger R. The genetic architecture of mitochondrial dysfunction in Parkinson\u2019s disease. Cell Tissue Res. 2018;373(1):21\u201337. https:\/\/doi.org\/10.1007\/s00441-017-2768-8.","journal-title":"Cell Tissue Res"},{"issue":"23","key":"1799_CR59","doi-asserted-by":"publisher","first-page":"17027","DOI":"10.3390\/IJMS242317027","volume":"24","author":"CJ Choong","year":"2023","unstructured":"Choong CJ, Mochizuki H. Involvement of Mitochondria in Parkinson\u2019s Disease. Int J Mol Sci. 2023;24(23):17027. https:\/\/doi.org\/10.3390\/IJMS242317027.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1799_CR60","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3233\/JAD-170585","volume":"62","author":"RH Swerdlow","year":"2018","unstructured":"Swerdlow RH. Mitochondria and Mitochondrial Cascades in Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis. 2018;62(3):1403\u201316. https:\/\/doi.org\/10.3233\/JAD-170585.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1799_CR61","doi-asserted-by":"publisher","first-page":"1188839","DOI":"10.3389\/FNINS.2023.1188839\/BIBTEX","volume":"17","author":"S Bagheri","year":"2023","unstructured":"Bagheri S, et al. \u201cNeuroprotective effects of coenzyme Q10 on neurological diseases: a review article.\u201d Front Neurosci. 2023;17:1188839. https:\/\/doi.org\/10.3389\/FNINS.2023.1188839\/BIBTEX.","journal-title":"Front Neurosci"},{"issue":"4","key":"1799_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.pathophys.2011.05.004","volume":"18","author":"A Nezhadi","year":"2011","unstructured":"Nezhadi A, et al. BMSC and CoQ10 improve behavioural recovery and histological outcome in rat model of Parkinson\u2019s disease. Pathophysiology. 2011;18(4):317\u201324. https:\/\/doi.org\/10.1016\/j.pathophys.2011.05.004.","journal-title":"Pathophysiology"},{"issue":"11","key":"1799_CR63","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.freeradbiomed.2010.08.028","volume":"49","author":"A Ghosh","year":"2010","unstructured":"Ghosh A, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson\u2019s disease model. Free Radic Biol Med. 2010;49(11):1674\u201384. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.08.028.","journal-title":"Free Radic Biol Med"},{"issue":"1\u20134","key":"1799_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/biof.5520250127","volume":"25","author":"RB Singh","year":"2005","unstructured":"Singh RB, Niaz MA, Kumar A, Sindberg CD, Moesgaard S, Littarru GP. Effect on absorption and oxidative stress of different oral Coenzyme Q 10 dosages and intake strategy in healthy men. BioFactors. 2005;25(1\u20134):219\u201324. https:\/\/doi.org\/10.1002\/biof.5520250127.","journal-title":"BioFactors"},{"issue":"5","key":"1799_CR65","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","volume":"31","author":"ZH Wang","year":"2010","unstructured":"Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010;31(5):908\u201315. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.09.104.","journal-title":"Biomaterials"},{"key":"1799_CR66","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/14651858.cd008150.pub2","volume":"12","author":"J Liu","year":"2011","unstructured":"Liu J, Wang L, Zhan S-Y, Xia Y. Coenzyme Q10 for Parkinson\u2019s disease. Cochrane Database Syst Rev. 2011;12:2011. https:\/\/doi.org\/10.1002\/14651858.cd008150.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"May","key":"1799_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","volume":"49","author":"Y Wu","year":"2019","unstructured":"Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion. 2019;49(May):35\u201345. https:\/\/doi.org\/10.1016\/j.mito.2019.07.003.","journal-title":"Mitochondrion"},{"key":"1799_CR68","doi-asserted-by":"publisher","unstructured":"A. Singh, R. Kukreti, L. Saso, and S. Kukreti, \u201cSingh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019). Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules (Basel, Switzerland), 24(8), 1583. https:\/\/doi.org\/10.3390\/molecules24081583,\u201d Molecules, 24, 8, 1\u201320, 2019.","DOI":"10.3390\/molecules24081583"},{"key":"1799_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11910-018-0829-3","volume":"18","author":"JS Park","year":"2018","unstructured":"Park JS, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson\u2019s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18:5. https:\/\/doi.org\/10.1007\/s11910-018-0829-3.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"1799_CR70","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST20170501","volume":"46","author":"R Macdonald","year":"2018","unstructured":"Macdonald R, Barnes K, Hastings C, Mortiboys H. Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: Can mitochondria be targeted therapeutically? Biochem Soc Trans. 2018;46(4):891\u2013909. https:\/\/doi.org\/10.1042\/BST20170501.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"1799_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","volume":"42","author":"M Nguyen","year":"2019","unstructured":"Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson\u2019s Disease. Trends Neurosci. 2019;42(2):140\u20139. https:\/\/doi.org\/10.1016\/j.tins.2018.11.001.","journal-title":"Trends Neurosci"},{"issue":"4","key":"1799_CR72","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"E T\u00f6nnies","year":"2017","unstructured":"T\u00f6nnies E, Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis. 2017;57(4):1105\u201321. https:\/\/doi.org\/10.3233\/JAD-161088.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1799_CR73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.phrs.2018.03.010","volume":"131","author":"V Shoshan-Barmatz","year":"2018","unstructured":"Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, Gupta R. VDAC1, mitochondrial dysfunction, and Alzheimer\u2019s disease. Pharmacol Res. 2018;131:87\u2013101. https:\/\/doi.org\/10.1016\/j.phrs.2018.03.010.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1799_CR74","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12640-017-9766-1","volume":"32","author":"M Jodeiri Farshbaf","year":"2017","unstructured":"Jodeiri Farshbaf M, Ghaedi K. Huntington\u2019s Disease and Mitochondria. Neurotox Res. 2017;32(3):518\u201329. https:\/\/doi.org\/10.1007\/s12640-017-9766-1.","journal-title":"Neurotox Res"},{"issue":"2018","key":"1799_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","volume":"1049","author":"C Carmo","year":"2018","unstructured":"Carmo C, Naia L, Lopes C, Rego AC. Mitochondrial dysfunction in huntington\u2019s disease. Adv Exp Med Biol. 2018;1049(2018):59\u201383. https:\/\/doi.org\/10.1007\/978-3-319-71779-1_3.","journal-title":"Adv Exp Med Biol"},{"key":"1799_CR76","doi-asserted-by":"publisher","first-page":"132933","DOI":"10.1016\/j.neulet.2017.06.052","volume":"710","author":"EF Smith","year":"2019","unstructured":"Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. https:\/\/doi.org\/10.1016\/j.neulet.2017.06.052.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1799_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm10030101","volume":"10","author":"L Le Gall","year":"2020","unstructured":"Le Gall L, Anakor E, Connolly O, Vijayakumar UG, Duddy WJ, Duguez S. Molecular and cellular mechanisms affected in als. J Pers Med. 2020;10(3):1\u201334. https:\/\/doi.org\/10.3390\/jpm10030101.","journal-title":"J Pers Med"},{"key":"1799_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2020.00679","volume":"14","author":"ML Cali\u00f3","year":"2020","unstructured":"Cali\u00f3 ML, Henriques E, Siena A, Bertoncini CRA, Gil-Mohapel J, Rosenstock TR. Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment. Front Neurosci. 2020;14:1\u201318. https:\/\/doi.org\/10.3389\/fnins.2020.00679.","journal-title":"Front Neurosci"},{"issue":"1","key":"1799_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14802\/jmd.22141","volume":"16","author":"Y Cha","year":"2023","unstructured":"Cha Y, Park TY, Leblanc P, Kim KS. Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson\u2019s Disease. J Mov Disord. 2023;16(1):22\u201341. https:\/\/doi.org\/10.14802\/jmd.22141.","journal-title":"J Mov Disord"},{"issue":"5","key":"1799_CR80","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/JPD-230372","volume":"14","author":"A Demailly","year":"2024","unstructured":"Demailly A, Moreau C, Devos D. Effectiveness of Continuous Dopaminergic Therapies in Parkinson\u2019s Disease: A Review of L-DOPA Pharmacokinetics\/Pharmacodynamics. J Parkinsons Dis. 2024;14(5):925\u201339. https:\/\/doi.org\/10.3233\/JPD-230372.","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"1799_CR81","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1242\/jcs.03443","volume":"120","author":"W Mandemakers","year":"2007","unstructured":"Mandemakers W, Morais VA, De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci. 2007;120(10):1707\u201316. https:\/\/doi.org\/10.1242\/jcs.03443.","journal-title":"J Cell Sci"},{"key":"1799_CR82","doi-asserted-by":"publisher","unstructured":"E. Tresse et al., \u201cMitochondrial DNA damage triggers spread of Parkinson\u2019s disease-like pathology,\u201d. Mol Psychiatry. 2023 2811, 28, 11, 4902\u20134914, 2023, https:\/\/doi.org\/10.1038\/s41380-023-02251-4","DOI":"10.1038\/s41380-023-02251-4"},{"issue":"14","key":"1799_CR83","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cub.2006.06.054","volume":"16","author":"HM McBride","year":"2006","unstructured":"McBride HM, Neuspiel M, Wasiak S. Mitochondria: More Than Just a Powerhouse. Curr Biol. 2006;16(14):551\u201360. https:\/\/doi.org\/10.1016\/j.cub.2006.06.054.","journal-title":"Curr Biol"},{"issue":"2","key":"1799_CR84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","volume":"552","author":"JF Turrens","year":"2003","unstructured":"Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552(2):335\u201344. https:\/\/doi.org\/10.1113\/jphysiol.2003.049478.","journal-title":"J Physiol"},{"issue":"6","key":"1799_CR85","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1006\/scdb.2001.0282","volume":"12","author":"IG Kirkinezos","year":"2001","unstructured":"Kirkinezos IG, Moraes CT. Reactive oxygen species and mitochondrial diseases. Semin Cell Dev Biol. 2001;12(6):449\u201357. https:\/\/doi.org\/10.1006\/scdb.2001.0282.","journal-title":"Semin Cell Dev Biol"},{"issue":"13","key":"1799_CR86","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/IJMS25137183","volume":"25","author":"M Muleiro Alvarez","year":"2024","unstructured":"Muleiro Alvarez M, et al. A Comprehensive Approach to Parkinson\u2019s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects. Int J Mol Sci. 2024;25(13):7183. https:\/\/doi.org\/10.3390\/IJMS25137183.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1799_CR87","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.tibs.2010.04.002","volume":"35","author":"RB Hamanaka","year":"2010","unstructured":"Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci. 2010;35(9):505\u201313. https:\/\/doi.org\/10.1016\/j.tibs.2010.04.002.","journal-title":"Trends Biochem Sci"},{"issue":"3\u20134","key":"1799_CR88","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0891-5849(00)00317-8","volume":"29","author":"E Cadenas","year":"2000","unstructured":"Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000;29(3\u20134):222\u201330. https:\/\/doi.org\/10.1016\/S0891-5849(00)00317-8.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"1799_CR89","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.bbadis.2013.09.007","volume":"1842","author":"H Jin","year":"2014","unstructured":"Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson\u2019s disease: Preclinical and clinical outcomes. Biochim Biophys Acta - Mol Basis Dis. 2014;1842(8):1282\u201394. https:\/\/doi.org\/10.1016\/j.bbadis.2013.09.007.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"3","key":"1799_CR90","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/iub.1147","volume":"65","author":"A Olszewska","year":"2013","unstructured":"Olszewska A, Szewczyk A. Mitochondria as a pharmacological target: Magnum overview. IUBMB Life. 2013;65(3):273\u201381. https:\/\/doi.org\/10.1002\/iub.1147.","journal-title":"IUBMB Life"},{"issue":"4","key":"1799_CR91","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajme.2017.09.001","volume":"54","author":"OM Ighodaro","year":"2018","unstructured":"Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54(4):287\u201393. https:\/\/doi.org\/10.1016\/j.ajme.2017.09.001.","journal-title":"Alexandria J Med"},{"issue":"8","key":"1799_CR92","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0973-7847.70902","volume":"4","author":"V Lobo","year":"2010","unstructured":"Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118\u201326. https:\/\/doi.org\/10.4103\/0973-7847.70902.","journal-title":"Pharmacogn Rev"},{"issue":"14","key":"1799_CR93","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.addr.2009.06.008","volume":"61","author":"VE Kagan","year":"2009","unstructured":"Kagan VE, et al. Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. Adv Drug Deliv Rev. 2009;61(14):1375\u201385. https:\/\/doi.org\/10.1016\/j.addr.2009.06.008.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1799_CR94","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.bbadis.2008.12.006","volume":"1792","author":"AHK Tsang","year":"2009","unstructured":"Tsang AHK, Chung KKK. Oxidative and nitrosative stress in Parkinson\u2019s disease. Biochim Biophys Acta - Mol Basis Dis. 2009;1792(7):643\u201350. https:\/\/doi.org\/10.1016\/j.bbadis.2008.12.006.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"2","key":"1799_CR95","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT, et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson\u2019s Disease. J Neurochem. 1989;52(2):381\u20139. https:\/\/doi.org\/10.1111\/j.1471-4159.1989.tb09133.x.","journal-title":"J Neurochem"},{"issue":"3","key":"1799_CR96","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, et al. Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36(3):348\u201355. https:\/\/doi.org\/10.1002\/ana.410360305.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"1799_CR97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mrgentox.2008.09.013","volume":"674","author":"L Migliore","year":"2009","unstructured":"Migliore L, Copped\u00e8 F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res - Genet Toxicol Environ Mutagen. 2009;674(1\u20132):73\u201384. https:\/\/doi.org\/10.1016\/j.mrgentox.2008.09.013.","journal-title":"Mutat Res - Genet Toxicol Environ Mutagen"},{"issue":"4","key":"1799_CR98","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1006\/nbdi.2000.0319","volume":"7","author":"Y Zhang","year":"2000","unstructured":"Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of parkinson\u2019s disease. Neurobiol Dis. 2000;7(4):240\u201350. https:\/\/doi.org\/10.1006\/nbdi.2000.0319.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1799_CR99","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/IJMS20030728","volume":"20","author":"Z Zhu","year":"2019","unstructured":"Zhu Z, et al. Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson\u2019s Disease. Int J Mol Sci. 2019;20(3):728. https:\/\/doi.org\/10.3390\/IJMS20030728.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1799_CR100","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.BIOCEL.2015.03.006","volume":"64","author":"S Gao","year":"2015","unstructured":"Gao S, Duan C, Gao G, Wang X, Yang H. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1\/S6K1 signaling. Int J Biochem Cell Biol. 2015;64(6):25\u201333. https:\/\/doi.org\/10.1016\/J.BIOCEL.2015.03.006.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1799_CR101","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease. J Neurosci. 2010;30(3):1166\u201375. https:\/\/doi.org\/10.1523\/JNEUROSCI.3944-09.2010.","journal-title":"J Neurosci"},{"key":"1799_CR102","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3389\/FNINS.2019.01028","volume":"13","author":"M Ramalingam","year":"2019","unstructured":"Ramalingam M, Huh YJ, Il Lee Y. The Impairments of \u03b1-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson\u2019s Disease. Front Neurosci. 2019;13:1028. https:\/\/doi.org\/10.3389\/FNINS.2019.01028.","journal-title":"Front Neurosci"},{"issue":"1","key":"1799_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"SYY Pang","year":"2022","unstructured":"Pang SYY, et al. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener. 2022;11(1):1\u201314. https:\/\/doi.org\/10.1186\/s40035-022-00281-6.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1799_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS22010189","volume":"22","author":"O Damri","year":"2020","unstructured":"Damri O, Shemesh N, Agam G. Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer\u2019s Disease, Lithium, and Autophagy. Int J Mol Sci. 2020;22(1):1\u201317. https:\/\/doi.org\/10.3390\/IJMS22010189.","journal-title":"Int J Mol Sci"},{"issue":"January","key":"1799_CR105","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ibneur.2022.10.006","volume":"13","author":"T Mar\u00edn","year":"2022","unstructured":"Mar\u00edn T, et al. The c-Abl\/p73 pathway induces neurodegeneration in a Parkinson\u2019s disease model. IBRO Neurosci Reports. 2022;13(January):378\u201387. https:\/\/doi.org\/10.1016\/j.ibneur.2022.10.006.","journal-title":"IBRO Neurosci Reports"},{"issue":"7","key":"1799_CR106","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"P Breedveld","year":"2005","unstructured":"Breedveld P, et al. The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Pat. Cancer Res. 2005;65(7):2577\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2416.","journal-title":"Cancer Res"},{"key":"1799_CR107","doi-asserted-by":"publisher","first-page":"15_supplement","DOI":"10.1212\/WNL.94.15_SUPPLEMENT.5357","volume":"94","author":"A Fowler","year":"2020","unstructured":"Fowler A, et al. Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the CSF of individuals with Parkinson\u2019s disease (5357). Neurology. 2020;94:15_supplement. https:\/\/doi.org\/10.1212\/WNL.94.15_SUPPLEMENT.5357.","journal-title":"Neurology"},{"issue":"2","key":"1799_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10020371","volume":"10","author":"NA Gouda","year":"2022","unstructured":"Gouda NA, Elkamhawy A, Cho J. Emerging Therapeutic Strategies for Parkinson\u2019s Disease and Future Prospects: A 2021 Update. Biomedicines. 2022;10(2):1\u201340. https:\/\/doi.org\/10.3390\/biomedicines10020371.","journal-title":"Biomedicines"},{"key":"1799_CR109","doi-asserted-by":"publisher","unstructured":"E. M. Rocha, B. De Miranda, and L. H. Sanders, \u201cAlpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease,\u201d. Neurobiol Dis. 109 Part B, 2018, 249\u2013257, 2018, https:\/\/doi.org\/10.1016\/j.nbd.2017.04.004.","DOI":"10.1016\/j.nbd.2017.04.004"},{"key":"1799_CR110","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/FNINS.2017.00248\/PDF","volume":"11","author":"EL Gorenberg","year":"2017","unstructured":"Gorenberg EL, Chandra SS. The role of co-chaperones in synaptic proteostasis and neurodegenerative disease. Front Neurosci. 2017;11:248. https:\/\/doi.org\/10.3389\/FNINS.2017.00248\/PDF.","journal-title":"Front Neurosci"},{"issue":"5","key":"1799_CR111","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/J.PHRS.2011.01.004","volume":"63","author":"Z Liu","year":"2011","unstructured":"Liu Z, Yu Y, Li X, Ross CA, Smith WW. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol Res. 2011;63(5):439\u201344. https:\/\/doi.org\/10.1016\/J.PHRS.2011.01.004.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1799_CR112","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/CN3001203","volume":"4","author":"PK Singh","year":"2013","unstructured":"Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. Curcumin modulates \u03b1-synuclein aggregation and toxicity. ACS Chem Neurosci. 2013;4(3):393\u2013407. https:\/\/doi.org\/10.1021\/CN3001203.","journal-title":"ACS Chem Neurosci"},{"key":"1799_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8:1. https:\/\/doi.org\/10.1038\/S41598-018-34490-9.","journal-title":"Sci Rep"},{"issue":"3","key":"1799_CR114","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.trci.2016.06.004","volume":"2","author":"JM Levenson","year":"2016","unstructured":"Levenson JM, et al. NPT088 reduces both amyloid-\u03b2 and tau pathologies in transgenic mice. Alzheimer\u2019s Dement Transl Res Clin Interv. 2016;2(3):141\u201355. https:\/\/doi.org\/10.1016\/j.trci.2016.06.004.","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"issue":"4","key":"1799_CR115","doi-asserted-by":"publisher","first-page":"228","DOI":"10.14283\/JPAD.2019.37","volume":"6","author":"D Michelson","year":"2019","unstructured":"Michelson D, et al. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer\u2019s Disease. J Prev Alzheimer\u2019s Dis. 2019;6(4):228\u201331. https:\/\/doi.org\/10.14283\/JPAD.2019.37.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"D1","key":"1799_CR116","doi-asserted-by":"publisher","first-page":"D328","DOI":"10.1093\/nar\/gkz995","volume":"48","author":"M Zahn-Zabal","year":"2020","unstructured":"Zahn-Zabal M, et al. The neXtProt knowledgebase in 2020: Data, tools and usability improvements. Nucleic Acids Res. 2020;48(D1):D328\u201334. https:\/\/doi.org\/10.1093\/nar\/gkz995.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"1799_CR117","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/J.YMTHE.2017.11.015","volume":"26","author":"D Alarc\u00f3n-Ar\u00eds","year":"2018","unstructured":"Alarc\u00f3n-Ar\u00eds D, et al. Selective \u03b1-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson\u2019s Disease. Mol Ther. 2018;26(2):550\u201367. https:\/\/doi.org\/10.1016\/J.YMTHE.2017.11.015.","journal-title":"Mol Ther"},{"issue":"1","key":"1799_CR118","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/S41531-018-0062-4","volume":"4","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee D, et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model. Npj Park Dis. 2018;4(1):25. https:\/\/doi.org\/10.1038\/S41531-018-0062-4.","journal-title":"Npj Park Dis"},{"issue":"6","key":"1799_CR119","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/S00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 2013;125(6):795\u2013813. https:\/\/doi.org\/10.1007\/S00401-013-1114-9.","journal-title":"Acta Neuropathol"},{"issue":"8797","key":"1799_CR120","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/0140-6736(92)90313-R","volume":"339","author":"R Hishida","year":"1992","unstructured":"Hishida R, Kurahashi K, Narita S, Baba T, Matsunaga M. \u2018Wearing-off\u2019 and \u03b22-adrenoceptor agonist in Parkinson\u2019s disease. Lancet. 1992;339(8797):870. https:\/\/doi.org\/10.1016\/0140-6736(92)90313-R.","journal-title":"Lancet"},{"issue":"9","key":"1799_CR121","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/0963689717721234","volume":"26","author":"DS Kim","year":"2017","unstructured":"Kim DS, Il Choi H, Wang Y, Luo Y, Hoffer BJ, Greig NH. A New Treatment Strategy for Parkinson\u2019s Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplant. 2017;26(9):1560\u201371. https:\/\/doi.org\/10.1177\/0963689717721234.","journal-title":"Cell Transplant."},{"issue":"5","key":"1799_CR122","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/J.DRUDIS.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today. 2016;21(5):802\u201318. https:\/\/doi.org\/10.1016\/J.DRUDIS.2016.01.013.","journal-title":"Drug Discov Today"},{"issue":"3","key":"1799_CR123","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/JPET.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry T, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958\u201366. https:\/\/doi.org\/10.1124\/JPET.300.3.958.","journal-title":"J Pharmacol Exp Ther"},{"key":"1799_CR124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/J.EXPNEUROL.2016.11.010","volume":"288","author":"Y Li","year":"2017","unstructured":"Li Y, Wu KJ, Yu SJ, Tamargo IA, Wang Y, Greig NH. Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol. 2017;288:104\u201313. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2016.11.010.","journal-title":"Exp Neurol"},{"key":"1799_CR125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1523\/ENEURO.0183-16.2016","volume":"3","author":"H Jiang","year":"2016","unstructured":"Jiang H, et al. Adult Conditional Knockout of PGC-1\u03b1 Leads to Loss of Dopamine Neurons. eNeuro. 2016;3:4. https:\/\/doi.org\/10.1523\/ENEURO.0183-16.2016.","journal-title":"eNeuro"},{"issue":"6","key":"1799_CR126","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1007\/S12035-015-9299-7","volume":"53","author":"Q Ye","year":"2016","unstructured":"Ye Q, et al. Overexpression of PGC-1\u03b1 Influences Mitochondrial Signal Transduction of Dopaminergic Neurons. Mol Neurobiol. 2016;53(6):3756\u201370. https:\/\/doi.org\/10.1007\/S12035-015-9299-7.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1799_CR127","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/S41598-018-19479-8","volume":"8","author":"J Magalhaes","year":"2018","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8(1):1385. https:\/\/doi.org\/10.1038\/S41598-018-19479-8.","journal-title":"Sci Rep"},{"issue":"4","key":"1799_CR128","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/J.CELREP.2016.12.090","volume":"18","author":"Y Lee","year":"2017","unstructured":"Lee Y, et al. PINK1 primes parkin-mediated ubiquitination of PARIS in dopaminergic neuronal survival. Cell Rep. 2017;18(4):918. https:\/\/doi.org\/10.1016\/J.CELREP.2016.12.090.","journal-title":"Cell Rep"},{"issue":"6","key":"1799_CR129","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.33263\/BRIAC106.71357151","volume":"10","author":"MM Rahman","year":"2020","unstructured":"Rahman MM, Ferdous KS, Ahmed M. Emerging promise of nanoparticle-based treatment for Parkinson\u2019s disease. Biointerface Res Appl Chem. 2020;10(6):7135\u201351. https:\/\/doi.org\/10.33263\/BRIAC106.71357151.","journal-title":"Biointerface Res Appl Chem"},{"key":"1799_CR130","doi-asserted-by":"publisher","unstructured":"M. Adil, U. Jiba, A. Khan, M. Shahrukh, N. Hasan, and F. J. Ahmad, \u201cAdvancements in ischemic stroke management: Transition from traditional to nanotechnological approaches,\u201d. J Drug Deliv Sci Technol. 102 Part A, 2024, 106318, 2024, https:\/\/doi.org\/10.1016\/j.jddst.2024.106318","DOI":"10.1016\/j.jddst.2024.106318"},{"issue":"45","key":"1799_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adma.201805368","volume":"31","author":"H Wang","year":"2019","unstructured":"Wang H, Wan K, Shi X. Recent Advances in Nanozyme Research. Adv Mater. 2019;31(45):1\u201310. https:\/\/doi.org\/10.1002\/adma.201805368.","journal-title":"Adv Mater"},{"issue":"2","key":"1799_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9020122","volume":"9","author":"P Andreeva-Gateva","year":"2020","unstructured":"Andreeva-Gateva P, Traikov L, Sabit Z, Bakalov D, Tafradjiiska-Hadjiolova R. Antioxidant effect of alpha-lipoic acid in 6-hydroxydopamine unilateral intrastriatal injected rats. Antioxidants. 2020;9(2):1\u201313. https:\/\/doi.org\/10.3390\/antiox9020122.","journal-title":"Antioxidants"},{"key":"1799_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.707441","volume":"9","author":"FLG Zoey","year":"2021","unstructured":"Zoey FLG, Palanivel M, Padmanabhan P, Guly\u00e1s B. Parkinson\u2019s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation. Front Cell Dev Biol. 2021;9:1\u201315. https:\/\/doi.org\/10.3389\/fcell.2021.707441.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1799_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14051080","volume":"14","author":"Y Casanova","year":"2022","unstructured":"Casanova Y, et al. Micro-and Nano-Systems Developed for Tolcapone in Parkinson\u2019s Disease. Pharmaceutics. 2022;14(5):1\u201315. https:\/\/doi.org\/10.3390\/pharmaceutics14051080.","journal-title":"Pharmaceutics"},{"issue":"33","key":"1799_CR135","doi-asserted-by":"publisher","first-page":"35223","DOI":"10.1021\/acsomega.4c01774","volume":"9","author":"O Ozceylan","year":"2024","unstructured":"Ozceylan O, Sezgin-Bayindir Z. Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases. ACS Omega. 2024;9(33):35223\u201342. https:\/\/doi.org\/10.1021\/acsomega.4c01774.","journal-title":"ACS Omega"},{"issue":"4","key":"1799_CR136","doi-asserted-by":"publisher","first-page":"s1185","DOI":"10.5530\/ijper.58.4s.116","volume":"58","author":"R Palaniyappan","year":"2024","unstructured":"Palaniyappan R, et al. Nanotechnology-Driven Approaches in Overcoming Drug Delivery Challenges for Neurodegenerative Diseases. Indian J Pharm Educ Res. 2024;58(4):s1185\u2013200. https:\/\/doi.org\/10.5530\/ijper.58.4s.116.","journal-title":"Indian J Pharm Educ Res"},{"key":"1799_CR137","doi-asserted-by":"publisher","first-page":"102426","DOI":"10.1016\/j.jddst.2021.102426","volume":"62","author":"A Shah","year":"2021","unstructured":"Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol. 2021;62:102426. https:\/\/doi.org\/10.1016\/j.jddst.2021.102426.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1799_CR138","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtice.2018.03.028","volume":"87","author":"YC Kuo","year":"2018","unstructured":"Kuo YC, Rajesh R. Current development of nanocarrier delivery systems for Parkinson\u2019s disease pharmacotherapy. J Taiwan Inst Chem Eng. 2018;87:15\u201325. https:\/\/doi.org\/10.1016\/j.jtice.2018.03.028.","journal-title":"J Taiwan Inst Chem Eng"},{"issue":"2","key":"1799_CR139","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/wnan.1364","volume":"8","author":"BL Banik","year":"2016","unstructured":"Banik BL, Fattahi P, Brown JL. Polymeric nanoparticles: The future of nanomedicine. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2016;8(2):271\u201399. https:\/\/doi.org\/10.1002\/wnan.1364.","journal-title":"Wiley Interdiscip Rev Nanomedicine Nanobiotechnology"},{"issue":"2","key":"1799_CR140","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/polym16020249","volume":"16","author":"S Andrade","year":"2024","unstructured":"Andrade S, Ramalho MJ, Loureiro JA. Polymeric Nanoparticles for Biomedical Applications. Polymers (Basel). 2024;16(2):2\u20135. https:\/\/doi.org\/10.3390\/polym16020249.","journal-title":"Polymers (Basel)"},{"key":"1799_CR141","doi-asserted-by":"publisher","unstructured":"R. Hanumanthappa et al., \u201cRecent advances in therapeutic strategies for Alzheimer\u2019s and Parkinson\u2019s disease using protein\/peptide co-modified polymer nanoparticles,\u201d. Neuroprotection 1\u201321, 2024, https:\/\/doi.org\/10.1002\/nep3.60","DOI":"10.1002\/nep3.60"},{"issue":"3","key":"1799_CR142","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jtumed.2024.04.004","volume":"19","author":"YSM Elmahboub","year":"2024","unstructured":"Elmahboub YSM, Elkordy AA. Polymeric nanoparticles: A promising strategy for treatment of Alzheimer\u2019s disease. J Taibah Univ Med Sci. 2024;19(3):549\u201365. https:\/\/doi.org\/10.1016\/j.jtumed.2024.04.004.","journal-title":"J Taibah Univ Med Sci"},{"key":"1799_CR143","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.nxnano.2023.100013","volume":"2","author":"H Bhardwaj","year":"2023","unstructured":"Bhardwaj H, Jangde RK. Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications. Next Nanotechnol. 2023;2:100013. https:\/\/doi.org\/10.1016\/j.nxnano.2023.100013.","journal-title":"Next Nanotechnol."},{"issue":"1","key":"1799_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jfb10010004","volume":"10","author":"E Calzoni","year":"2019","unstructured":"Calzoni E, Cesaretti A, Polchi A, Di Michele A, Tancini B, Emiliani C. Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. J Funct Biomater. 2019;10(1):1\u201315. https:\/\/doi.org\/10.3390\/jfb10010004.","journal-title":"J Funct Biomater"},{"key":"1799_CR145","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","volume":"190","author":"L Casettari","year":"2014","unstructured":"Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release. 2014;190:189\u2013200. https:\/\/doi.org\/10.1016\/j.jconrel.2014.05.003.","journal-title":"J Control Release"},{"issue":"7","key":"1799_CR146","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"G Leyva-G\u00f3mez","year":"2015","unstructured":"Leyva-G\u00f3mez G, Cort\u00e9s H, Maga\u00f1a JJ, Leyva-Garc\u00eda N, Quintanar-Guerrero D, Flor\u00e1n B. Nanoparticle technology for treatment of Parkinson\u2019s disease: the role of surface phenomena in reaching the brain. Drug Discov Today. 2015;20(7):824\u201337. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.009.","journal-title":"Drug Discov Today"},{"issue":"32","key":"1799_CR147","doi-asserted-by":"publisher","first-page":"13089","DOI":"10.1073\/PNAS.1105786108\/SUPPL_FILE\/PNAS.1105786108_SI.PDF","volume":"108","author":"BE Eckenroth","year":"2011","unstructured":"Eckenroth BE, Steere AN, Chasteen ND, Everse SJ, Mason AB. How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pH. Proc Natl Acad Sci U S A. 2011;108(32):13089\u201394. https:\/\/doi.org\/10.1073\/PNAS.1105786108\/SUPPL_FILE\/PNAS.1105786108_SI.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1799_CR148","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.reactfunctpolym.2010.10.009","volume":"71","author":"K Miyata","year":"2011","unstructured":"Miyata K, Christie RJ, Kataoka K. Polymeric micelles for nano-scale drug delivery. React Funct Polym. 2011;71(3):227\u201334. https:\/\/doi.org\/10.1016\/j.reactfunctpolym.2010.10.009.","journal-title":"React Funct Polym"},{"issue":"2","key":"1799_CR149","doi-asserted-by":"publisher","first-page":"33387","DOI":"10.26717\/bjstr.2022.42.006713","volume":"42","author":"Y Pathak","year":"2022","unstructured":"Pathak Y. \u2018Nanomedicine and Nano Formulations for Neurodegenerative Diseases.\u2019 Biomed J Sci Tech Res. 2022;42(2):33387\u201396. https:\/\/doi.org\/10.26717\/bjstr.2022.42.006713.","journal-title":"Biomed J Sci Tech Res"},{"key":"1799_CR150","doi-asserted-by":"publisher","first-page":"119653","DOI":"10.1016\/j.biomaterials.2019.119653","volume":"230","author":"D Carradori","year":"2020","unstructured":"Carradori D, et al. Retinoic acid-loaded NFL-lipid nanocapsules promote oligodendrogenesis in focal white matter lesion. Biomaterials. 2020;230:119653. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119653.","journal-title":"Biomaterials"},{"key":"1799_CR151","doi-asserted-by":"crossref","unstructured":"R. Eko, R. Gunawan, and A. Kadarohman, \u201cNanostarch based nanoencapsulation of Mucuna pruriens extract and its evaluation as anti-parkinsonian drug,\u201d 9 2024 100562","DOI":"10.1016\/j.cscee.2023.100562"},{"issue":"2018","key":"1799_CR152","doi-asserted-by":"publisher","first-page":"s305","DOI":"10.33549\/physiolres.933979","volume":"67","author":"J Kousalov\u00e1","year":"2018","unstructured":"Kousalov\u00e1 J, Etrych T. Polymeric nanogels as drug delivery systems. Physiol Res. 2018;67(2018):s305\u201317. https:\/\/doi.org\/10.33549\/physiolres.933979.","journal-title":"Physiol Res"},{"key":"1799_CR153","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.onano.2022.100111","volume":"9","author":"A Bhosale","year":"2023","unstructured":"Bhosale A, Paul G, Mazahir F, Yadav AK. Theoretical and applied concepts of nanocarriers for the treatment of Parkinson\u2019s diseases. OpenNano. 2023;9:100111. https:\/\/doi.org\/10.1016\/j.onano.2022.100111.","journal-title":"OpenNano"},{"key":"1799_CR154","doi-asserted-by":"publisher","first-page":"109607","DOI":"10.1016\/j.eurpolymj.2020.109607","volume":"128","author":"R Ansari","year":"2020","unstructured":"Ansari R, Sadati SM, Mozafari N, Ashrafi H, Azadi A. Carbohydrate polymer-based nanoparticle application in drug delivery for CNS-related disorders. Eur Polym J. 2020;128:109607. https:\/\/doi.org\/10.1016\/j.eurpolymj.2020.109607.","journal-title":"Eur Polym J"},{"issue":"5\u20136","key":"1799_CR155","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.drudis.2010.01.009","volume":"15","author":"AR Menjoge","year":"2010","unstructured":"Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5\u20136):171\u201385. https:\/\/doi.org\/10.1016\/j.drudis.2010.01.009.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1799_CR156","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/cn400182z","volume":"5","author":"L Xu","year":"2014","unstructured":"Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci. 2014;5(1):2\u201313. https:\/\/doi.org\/10.1021\/cn400182z.","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"1799_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9080330","volume":"9","author":"A Janaszewska","year":"2019","unstructured":"Janaszewska A, Lazniewska J, Trzepi\u0144ski P, Marcinkowska M, Klajnert-Maculewicz B. Cytotoxicity of dendrimers. Biomolecules. 2019;9(8):1\u201323. https:\/\/doi.org\/10.3390\/biom9080330.","journal-title":"Biomolecules"},{"issue":"12","key":"1799_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9120790","volume":"9","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Liu C, Pang Z. Dendrimer-based drug delivery systems for brain targeting. Biomolecules. 2019;9(12):1\u201329. https:\/\/doi.org\/10.3390\/biom9120790.","journal-title":"Biomolecules"},{"issue":"2","key":"1799_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pr11020319","volume":"11","author":"MD P\u00e9rez-Carri\u00f3n","year":"2023","unstructured":"P\u00e9rez-Carri\u00f3n MD, Posadas I. Dendrimers in Neurodegenerative Diseases. Processes. 2023;11(2):1\u201324. https:\/\/doi.org\/10.3390\/pr11020319.","journal-title":"Processes"},{"issue":"10","key":"1799_CR160","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1021\/acs.molpharmaceut.8b00537","volume":"15","author":"A Gothwal","year":"2018","unstructured":"Gothwal A, Nakhate KT, Alexander A, Ajazuddin A, Gupta U. Boosted Memory and Improved Brain Bioavailability of Rivastigmine: Targeting Effort to the Brain Using Covalently Tethered Lower Generation PAMAM Dendrimers with Lactoferrin. Mol Pharm. 2018;15(10):4538\u201349. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00537.","journal-title":"Mol Pharm"},{"key":"1799_CR161","doi-asserted-by":"publisher","unstructured":"R. S. Kibuuka, \u201cNanomedicine and Targeted Drug Delivery\u202f: Advances and Challenges,\u201d 2024, 12, 3, 24\u201328. https:\/\/doi.org\/10.59298\/INOSRAS\/2024\/12.3.2428","DOI":"10.59298\/INOSRAS\/2024\/12.3.2428"},{"issue":"1","key":"1799_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37819\/hb.1.1810","volume":"3","author":"Q Xu","year":"2024","unstructured":"Xu Q, Liu J, Liua H. Potential applications of nanomedicine in the treatment of Parkinson\u2019s disease. Hum Brain. 2024;3(1):1\u20138. https:\/\/doi.org\/10.37819\/hb.1.1810.","journal-title":"Hum Brain"},{"key":"1799_CR163","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","volume":"18","author":"G Unnikrishnan","year":"2023","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discov Nano. 2023;18:157. https:\/\/doi.org\/10.1186\/s11671-023-03943-0.","journal-title":"Discov Nano"},{"key":"1799_CR164","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/nano12142337","volume":"12","author":"S Martano","year":"2022","unstructured":"Martano S, De Matteis V, Cascione M, Rinaldi R. Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration. Nanomaterials. 2022;12:14. https:\/\/doi.org\/10.3390\/nano12142337.","journal-title":"Nanomaterials"},{"key":"1799_CR165","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jconrel.2018.12.036","volume":"295","author":"PV Torres-Ortega","year":"2019","unstructured":"Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ. Micro- and nanotechnology approaches to improve Parkinson\u2019s disease therapy. J Control Release. 2019;295:201\u201313. https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.036.","journal-title":"J Control Release"},{"issue":"12","key":"1799_CR166","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1039\/d0tb02957b","volume":"9","author":"F Persano","year":"2021","unstructured":"Persano F, Batasheva S, Fakhrullina G, Gigli G, Leporatti S, Fakhrullin R. Recent advances in the design of inorganic and nano-clay particles for the treatment of brain disorders. J Mater Chem B. 2021;9(12):2756\u201384. https:\/\/doi.org\/10.1039\/d0tb02957b.","journal-title":"J Mater Chem B"},{"issue":"5","key":"1799_CR167","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ajps.2018.09.005","volume":"14","author":"X Niu","year":"2019","unstructured":"Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian J Pharm Sci. 2019;14(5):480\u201396. https:\/\/doi.org\/10.1016\/j.ajps.2018.09.005.","journal-title":"Asian J Pharm Sci"},{"key":"1799_CR168","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijbiomac.2020.01.269","volume":"150","author":"S Asthana","year":"2020","unstructured":"Asthana S, et al. Interaction with zinc oxide nanoparticle kinetically traps \u03b1-synuclein fibrillation into off-pathway non-toxic intermediates. Int J Biol Macromol. 2020;150:68\u201379. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.01.269.","journal-title":"Int J Biol Macromol"},{"key":"1799_CR169","doi-asserted-by":"publisher","first-page":"105465","DOI":"10.1016\/j.microc.2020.105465","volume":"159","author":"M Cao","year":"2020","unstructured":"Cao M, Zheng L, Gu Y, Wang Y, Zhang H, Xu X. Electrostatic self-assembly to fabricate ZnO nanoparticles\/reduced graphene oxide composites for hypersensitivity detection of dopamine. Microchem J. 2020;159:105465. https:\/\/doi.org\/10.1016\/j.microc.2020.105465.","journal-title":"Microchem. J"},{"key":"1799_CR170","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ma15217664","volume":"15","author":"N Slekiene","year":"2022","unstructured":"Slekiene N, Snitka V, Bruzaite I, Ramanavicius A. Influence of TiO2 and ZnO Nanoparticles on \u03b1-Synuclein and \u03b2-Amyloid Aggregation and Formation of Protein Fibrils. Materials (Basel). 2022;15:21. https:\/\/doi.org\/10.3390\/ma15217664.","journal-title":"Materials (Basel)"},{"issue":"5","key":"1799_CR171","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","volume":"268","author":"J Baskin","year":"2021","unstructured":"Baskin J, Jeon JE, Lewis SJG. Nanoparticles for drug delivery in Parkinson\u2019s disease. J Neurol. 2021;268(5):1981\u201394. https:\/\/doi.org\/10.1007\/s00415-020-10291-x.","journal-title":"J Neurol"},{"key":"1799_CR172","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.cbi.2019.108935","volume":"316","author":"J Paunovic","year":"2020","unstructured":"Paunovic J, Vucevic D, Radosavljevic T, Mandi\u0107-Raj\u010devi\u0107 S, Pantic I. Iron-based nanoparticles and their potential toxicity: Focus on oxidative stress and apoptosis. Chem Biol Interact. 2020;316:108935. https:\/\/doi.org\/10.1016\/j.cbi.2019.108935.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"1799_CR173","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jsps.2023.01.009","volume":"31","author":"MS Attia","year":"2023","unstructured":"Attia MS, Yahya A, Monaem NA, Sabry SA. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer\u2019s and Parkinson\u2019s diseases. Saudi Pharm J. 2023;31(3):417\u201332. https:\/\/doi.org\/10.1016\/j.jsps.2023.01.009.","journal-title":"Saudi Pharm J"},{"key":"1799_CR174","doi-asserted-by":"publisher","first-page":"111657","DOI":"10.1016\/j.jphotobiol.2019.111657","volume":"201","author":"L Ling","year":"2019","unstructured":"Ling L, et al. Role of gold nanoparticle from Cinnamomum verum against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced mice model. J Photochem Photobiol B Biol. 2019;201:111657. https:\/\/doi.org\/10.1016\/j.jphotobiol.2019.111657.","journal-title":"J. Photochem Photobiol B Biol"},{"issue":"1","key":"1799_CR175","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ijbiomac.2020.12.130","volume":"169","author":"C Pang","year":"2021","unstructured":"Pang C, Zhang N, Falahati M. Acceleration of \u03b1-synuclein fibril formation and associated cytotoxicity stimulated by silica nanoparticles as a model of neurodegenerative diseases. Int J Biol Macromol. 2021;169(1):532\u201340. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.12.130.","journal-title":"Int J Biol Macromol"},{"key":"1799_CR176","doi-asserted-by":"publisher","unstructured":"A. Li et al., \u201cEmerging Nanotechnology for Treatment of Alzheimer\u2019s and Parkinson\u2019s Disease,\u201d. Front Bioeng Biotechnol 9 2021. https:\/\/doi.org\/10.3389\/fbioe.2021.672594","DOI":"10.3389\/fbioe.2021.672594"},{"issue":"2","key":"1799_CR177","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5152\/ABCR.2023.23150","volume":"5","author":"B Cicek","year":"2023","unstructured":"Cicek B, Danisman B. Cerium Oxide Nanoparticles Rescue Dopaminergic Neurons in Parkinson\u2019s Disease Model of SH-SY5Y Cells via Modulating Nrf2 Signaling and Ameliorating Apoptotic Cell Death. Arch Basic Clin Res. 2023;5(2):284\u201390. https:\/\/doi.org\/10.5152\/ABCR.2023.23150.","journal-title":"Arch Basic Clin Res"},{"issue":"1","key":"1799_CR178","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-015-0133-1","volume":"13","author":"H Sela","year":"2015","unstructured":"Sela H, Cohen H, Elia P, Zach R, Karpas Z, Zeiri Y. Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB). J Nanobiotechnology. 2015;13(1):71. https:\/\/doi.org\/10.1186\/s12951-015-0133-1.","journal-title":"J Nanobiotechnology"},{"key":"1799_CR179","doi-asserted-by":"publisher","first-page":"107161","DOI":"10.1016\/j.elecom.2021.107161","volume":"133","author":"X Qin","year":"2021","unstructured":"Qin X, et al. Modification of electrodes with self-assembled, close-packed AuNPs for improved signal reproducibility toward electrochemical detection of dopamine. Electrochem commun. 2021;133:107161. https:\/\/doi.org\/10.1016\/j.elecom.2021.107161.","journal-title":"Electrochem commun"},{"issue":"7","key":"1799_CR180","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1039\/d1ra06437a","volume":"12","author":"ED Aminabad","year":"2022","unstructured":"Aminabad ED, Mobed A, Hasanzadeh M, Hosseinpour Feizi MA, Safaralizadeh R, Seidi F. Sensitive immunosensing of \u03b1-synuclein protein in human plasma samples using gold nanoparticles conjugated with graphene: An innovative immuno-platform towards early stage identification of Parkinson\u2019s disease using point of care (POC) analysis. RSC Adv. 2022;12(7):4346\u201357. https:\/\/doi.org\/10.1039\/d1ra06437a.","journal-title":"RSC Adv"},{"issue":"2","key":"1799_CR181","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1039\/c8an01279b","volume":"144","author":"MNS Karabo\u01e7a","year":"2019","unstructured":"Karabo\u01e7a MNS, Sezgint\u00fcrk MK. Cerebrospinal fluid levels of alpha-synuclein measured using a poly-glutamic acid-modified gold nanoparticle-doped disposable neuro-biosensor system. Analyst. 2019;144(2):611\u201321. https:\/\/doi.org\/10.1039\/c8an01279b.","journal-title":"Analyst"},{"key":"1799_CR182","doi-asserted-by":"publisher","first-page":"105195","DOI":"10.1016\/j.microc.2020.105195","volume":"158","author":"D Tao","year":"2020","unstructured":"Tao D, et al. Ultrasensitive detection of alpha-synuclein oligomer using a PolyD-glucosamine\/gold nanoparticle\/carbon-based nanomaterials modified electrochemical immunosensor in human plasma. Microchem J. 2020;158:105195. https:\/\/doi.org\/10.1016\/j.microc.2020.105195.","journal-title":"Microchem J"},{"key":"1799_CR183","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biomaterials.2018.12.013","volume":"194","author":"G Gao","year":"2019","unstructured":"Gao G, Chen R, He M, Li J, Wang L, Sun T. Gold nanoclusters for Parkinson\u2019s disease treatment. Biomaterials. 2019;194:36\u201346. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.12.013.","journal-title":"Biomaterials"},{"issue":"4","key":"1799_CR184","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","volume":"51","author":"R Duwa","year":"2021","unstructured":"Duwa R, Jeong JH, Yook S. Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson\u2019s disease. J Pharm Investig. 2021;51(4):465\u201381. https:\/\/doi.org\/10.1007\/s40005-021-00521-3.","journal-title":"J Pharm Investig"},{"issue":"13","key":"1799_CR185","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2018.11.034","volume":"1707","author":"X Ge Liu","year":"2019","unstructured":"Ge Liu X, et al. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson\u2019s and Huntington\u2019s diseases. Brain Res. 2019;1707(13):141\u201353. https:\/\/doi.org\/10.1016\/j.brainres.2018.11.034.","journal-title":"Brain Res"},{"issue":"10","key":"1799_CR186","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.drudis.2015.06.008","volume":"20","author":"F Dilnawaz","year":"2015","unstructured":"Dilnawaz F, Sahoo SK. Therapeutic approaches of magnetic nanoparticles for the central nervous system. Drug Discovery Today. 2015;20(10):1256\u201364. https:\/\/doi.org\/10.1016\/j.drudis.2015.06.008.","journal-title":"Drug Discovery Today"},{"issue":"2","key":"1799_CR187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020654","volume":"22","author":"KY Kim","year":"2021","unstructured":"Kim KY, Chang KA. Therapeutic potential of magnetic nanoparticle-based human adipose-derived stem cells in a mouse model of parkinson\u2019s disease. Int J Mol Sci. 2021;22(2):1\u201310. https:\/\/doi.org\/10.3390\/ijms22020654.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1799_CR188","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/jfb10030032","volume":"10","author":"H Sch\u00f6neborn","year":"2019","unstructured":"Sch\u00f6neborn H, et al. Novel tools towards magnetic guidance of neurite growth: (I) guidance of magnetic nanoparticles into neurite extensions of induced human neurons and in vitro functionalization with Ras regulating proteins. J Funct Biomater. 2019;10(3):32. https:\/\/doi.org\/10.3390\/jfb10030032.","journal-title":"J Funct Biomater"},{"key":"1799_CR189","doi-asserted-by":"publisher","first-page":"115082","DOI":"10.1016\/j.ab.2023.115082","volume":"667","author":"N Upadhyay","year":"2023","unstructured":"Upadhyay N, et al. 2023 \u201cDevelopment of sensitive magnetic nanoparticle assisted rapid sandwich assay(s-MARSA) to monitor Parkinson\u2019s disease and Schizophrenia pharmacotherapy.\u201d Anal Biochem. 2023;667:115082. https:\/\/doi.org\/10.1016\/j.ab.2023.115082.","journal-title":"Anal Biochem"},{"issue":"1","key":"1799_CR190","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12951-016-0198-5","volume":"14","author":"SY Yang","year":"2016","unstructured":"Yang SY, et al. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnology. 2016;14(1):41. https:\/\/doi.org\/10.1186\/s12951-016-0198-5.","journal-title":"J Nanobiotechnology"},{"issue":"2020","key":"1799_CR191","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","volume":"156","author":"N Filipczak","year":"2020","unstructured":"Filipczak N, Pan J, Yalamarty SSK, Torchilin VP. Recent advancements in liposome technology. Adv Drug Deliv Rev. 2020;156(2020):4\u201322. https:\/\/doi.org\/10.1016\/j.addr.2020.06.022.","journal-title":"Adv Drug Deliv Rev"},{"key":"1799_CR192","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.actbio.2020.11.015","volume":"119","author":"YC Kuo","year":"2021","unstructured":"Kuo YC, Wang IH, Rajesh R. Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson\u2019s disease therapy. Acta Biomater. 2021;119:360\u201374. https:\/\/doi.org\/10.1016\/j.actbio.2020.11.015.","journal-title":"Acta Biomater."},{"issue":"16","key":"1799_CR193","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.3390\/ijms23169361","volume":"23","author":"K Jagaran","year":"2022","unstructured":"Jagaran K, Singh M. Lipid Nanoparticles: Promising Treatment Approach for Parkinson\u2019s Disease. Int J Mol Sci. 2022;23(16):9361. https:\/\/doi.org\/10.3390\/ijms23169361.","journal-title":"Int J Mol Sci"},{"key":"1799_CR194","doi-asserted-by":"publisher","first-page":"2382563","DOI":"10.1155\/2019\/2382563","volume":"2019","author":"B Gaba","year":"2019","unstructured":"Gaba B, et al. Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson\u2019s Disease Model. Biomed Res Int. 2019;2019:2382563. https:\/\/doi.org\/10.1155\/2019\/2382563.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1799_CR195","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12640-021-00362-w","volume":"39","author":"OV Ramires J\u00fanior","year":"2021","unstructured":"Ramires J\u00fanior OV, et al. Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson\u2019s Disease. Neurotox Res. 2021;39(3):787\u201399. https:\/\/doi.org\/10.1007\/s12640-021-00362-w.","journal-title":"Neurotox Res"},{"issue":"3","key":"1799_CR196","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1021\/acsbiomaterials.0c01474","volume":"7","author":"M Li","year":"2021","unstructured":"Li M, et al. Synthesis of Double Interfering Biodegradable Nano-MgO Micelle Composites and Their Effect on Parkinson\u2019s Disease. ACS Biomater Sci Eng. 2021;7(3):1216\u201329. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c01474.","journal-title":"ACS Biomater Sci Eng"},{"key":"1799_CR197","doi-asserted-by":"publisher","first-page":"119981","DOI":"10.1016\/j.ijpharm.2020.119981","volume":"591","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yang S, Huang L, Ho PCL. 2020 \u201cPoly (ethylene glycol)-block-poly (D, L-lactide) (PEG-PLA) micelles for brain delivery of baicalein through nasal route for potential treatment of neurodegenerative diseases due to oxidative stress and inflammation: An in vitro and in vivo study.\u201d Int J Pharm. 2020;591:119981. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119981.","journal-title":"Int J Pharm"},{"issue":"1","key":"1799_CR198","doi-asserted-by":"publisher","first-page":"01053","DOI":"10.3969\/j.issn.1001-9731.2021.01.009","volume":"52","author":"H Mao","year":"2021","unstructured":"Mao H, Xue M, Han G. Synthesis, properties and applications of fluorescent carbon dots. Gongneng Cailiao\/J Funct Mater. 2021;52(1):01053\u201363. https:\/\/doi.org\/10.3969\/j.issn.1001-9731.2021.01.009.","journal-title":"Gongneng Cailiao\/J Funct Mater"},{"issue":"1","key":"1799_CR199","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/jbm.a.36550","volume":"107","author":"L Farzin","year":"2019","unstructured":"Farzin L, Sheibani S, Moassesi ME, Shamsipur M. An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions. J Biomed Mater Res - Part A. 2019;107(1):251\u201385. https:\/\/doi.org\/10.1002\/jbm.a.36550.","journal-title":"J Biomed Mater Res - Part A"},{"issue":"18","key":"1799_CR200","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.3390\/ma13184004","volume":"13","author":"R Knoblauch","year":"2020","unstructured":"Knoblauch R, Geddes CD. Carbon nanodots in photodynamic antimicrobial therapy: A review. Materials (Basel). 2020;13(18):4004. https:\/\/doi.org\/10.3390\/ma13184004.","journal-title":"Materials (Basel)"},{"key":"1799_CR201","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.colsurfb.2017.11.055","volume":"162","author":"F Qu","year":"2018","unstructured":"Qu F, Huang W, You J. A fluorescent sensor for detecting dopamine and tyrosinase activity by dual-emission carbon dots and gold nanoparticles. Colloids Surfaces B Biointerfaces. 2018;162:212\u20139. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.11.055.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"1799_CR202","doi-asserted-by":"publisher","first-page":"338513","DOI":"10.1016\/j.aca.2021.338513","volume":"1165","author":"SW Park","year":"2021","unstructured":"Park SW, Kim TE, Jung YK. Glutathione-decorated fluorescent carbon quantum dots for sensitive and selective detection of levodopa. Anal Chim Acta. 2021;1165:338513. https:\/\/doi.org\/10.1016\/j.aca.2021.338513.","journal-title":"Anal. Chim. Acta"},{"issue":"46","key":"1799_CR203","doi-asserted-by":"publisher","first-page":"22387","DOI":"10.1039\/c9nr08194a","volume":"11","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, et al. Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood-brain barrier and inhibitors of \u03b2-amyloid. Nanoscale. 2019;11(46):22387\u201397. https:\/\/doi.org\/10.1039\/c9nr08194a.","journal-title":"Nanoscale"},{"key":"1799_CR204","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.cis.2020.102123","volume":"278","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Mohammadinejad R, Kailasa SK, Ahmadi Z, Afshar EG, Pardakhty A. Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: A review. Adv Colloid Interface Sci. 2020;278:102123. https:\/\/doi.org\/10.1016\/j.cis.2020.102123.","journal-title":"Adv Colloid Interface Sci"},{"key":"1799_CR205","doi-asserted-by":"publisher","first-page":"129698","DOI":"10.1016\/j.molstruc.2020.129698","volume":"1231","author":"E Ghazy","year":"2021","unstructured":"Ghazy E, Rahdar A, Barani M, Kyzas GZ. Nanomaterials for Parkinson disease: Recent progress. J Mol Struct. 2021;1231:129698. https:\/\/doi.org\/10.1016\/j.molstruc.2020.129698.","journal-title":"J Mol Struct"},{"issue":"41","key":"1799_CR206","doi-asserted-by":"publisher","first-page":"24386","DOI":"10.1039\/d0ra04599c","volume":"10","author":"SA Mathew","year":"2020","unstructured":"Mathew SA, Praveena P, Dhanavel S, Manikandan R, Senthilkumar S, Stephen A. Luminescent chitosan\/carbon dots as an effective nano-drug carrier for neurodegenerative diseases. RSC Adv. 2020;10(41):24386\u201396. https:\/\/doi.org\/10.1039\/d0ra04599c.","journal-title":"RSC Adv"},{"issue":"1","key":"1799_CR207","doi-asserted-by":"publisher","first-page":"39","DOI":"10.61797\/ijanca.v2i1.240","volume":"2","author":"V Mohan","year":"2023","unstructured":"Mohan V. Recent Advances of Carbon dots for Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases. Int J Adv Nano Comput Anal. 2023;2(1):39\u201359. https:\/\/doi.org\/10.61797\/ijanca.v2i1.240.","journal-title":"Int J Adv Nano Comput Anal"},{"issue":"13","key":"1799_CR208","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1039\/d1na00145k","volume":"3","author":"ES Seven","year":"2021","unstructured":"Seven ES, et al. Crossing the blood\u2013brain barrier with carbon dots: uptake mechanism and in vivo cargo delivery. Nanoscale Adv. 2021;3(13):3942\u201353. https:\/\/doi.org\/10.1039\/d1na00145k.","journal-title":"Nanoscale Adv"},{"key":"1799_CR209","doi-asserted-by":"publisher","unstructured":"L. Li et al., \u201cHydrophobic Carbon Dots Prevent \u03b1-Synucleinopathy and Suppress Neuroinflammation to Treat Parkinson\u2019s Disease,\u201d Aggregate, 2024. https:\/\/doi.org\/10.1002\/agt2.711","DOI":"10.1002\/agt2.711"},{"issue":"29","key":"1799_CR210","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1039\/c6ay00836d","volume":"8","author":"M Arvand","year":"2016","unstructured":"Arvand M, Abbasnejad S, Ghodsi N. Graphene quantum dots decorated with Fe3O4 nanoparticles\/functionalized multiwalled carbon nanotubes as a new sensing platform for electrochemical determination of l-DOPA in agricultural products. Anal Methods. 2016;8(29):5861\u20138. https:\/\/doi.org\/10.1039\/c6ay00836d.","journal-title":"Anal Methods"},{"key":"1799_CR211","doi-asserted-by":"publisher","first-page":"110651","DOI":"10.1016\/j.msec.2020.110651","volume":"110","author":"TK Henna","year":"2020","unstructured":"Henna TK, Pramod K. Graphene quantum dots redefine nanobiomedicine. Mater Sci Eng C. 2020;110:110651. https:\/\/doi.org\/10.1016\/j.msec.2020.110651.","journal-title":"Mater Sci Eng C"},{"issue":"2","key":"1799_CR212","doi-asserted-by":"publisher","first-page":"e100105","DOI":"10.5812\/thrita.100105","volume":"9","author":"B Hasannejadasl","year":"2021","unstructured":"Hasannejadasl B, Pooresmaeil Janbaz F, Choupani E, Fadaie M, Hamidinejad MA, Ahmadvand D. Quantum Dots Application in Neurodegenerative Diseases. Thrita. 2021;9(2):e100105. https:\/\/doi.org\/10.5812\/thrita.100105.","journal-title":"Thrita"},{"issue":"37","key":"1799_CR213","doi-asserted-by":"publisher","first-page":"19450","DOI":"10.1039\/d0nr05003b","volume":"12","author":"M Ghaeidamini","year":"2020","unstructured":"Ghaeidamini M, Bernson D, Sasanian N, Kumar R. Graphene oxide sheets and quantum dots inhibit a-synuclein amyloid formation by different mechanisms. Nanoscale. 2020;12(37):19450\u201360. https:\/\/doi.org\/10.1039\/d0nr05003b.","journal-title":"Nanoscale"},{"issue":"9","key":"1799_CR214","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","volume":"13","author":"D Kim","year":"2018","unstructured":"Kim D, et al. Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease. Nat Nanotechnol. 2018;13(9):812\u20138. https:\/\/doi.org\/10.1038\/s41565-018-0179-y.","journal-title":"Nat Nanotechnol"},{"key":"1799_CR215","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jconrel.2020.11.021","volume":"330","author":"A Akhtar","year":"2021","unstructured":"Akhtar A, et al. Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. J Control Release. 2021;330:1152\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.021.","journal-title":"J Control Release"},{"issue":"3","key":"1799_CR216","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/biomedicines12030549","volume":"12","author":"A Bougea","year":"2024","unstructured":"Bougea A. Some Novel Therapies in Parkinson\u2019s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomedicines. 2024;12(3):549. https:\/\/doi.org\/10.3390\/biomedicines12030549.","journal-title":"Biomedicines"},{"issue":"2","key":"1799_CR217","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/acs.molpharmaceut.0c00474","volume":"18","author":"AC Farr","year":"2021","unstructured":"Farr AC, Xiong MP. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Intracerebral Hemorrhage. Mol Pharm. 2021;18(2):593\u2013609. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00474.","journal-title":"Mol Pharm"},{"issue":"9","key":"1799_CR218","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.68419","volume":"16","author":"S Anwarkhan","year":"2024","unstructured":"Anwarkhan S, Koilpillai J, Narayanasamy D. Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies. Cureus. 2024;16(9):1\u201315. https:\/\/doi.org\/10.7759\/cureus.68419.","journal-title":"Cureus"},{"issue":"1","key":"1799_CR219","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12938-022-01062-y","volume":"22","author":"L Shabani","year":"2023","unstructured":"Shabani L, Abbasi M, Azarnew Z, Amani AM, Vaez A. Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience. Biomed Eng Online. 2023;22(1):1\u201341. https:\/\/doi.org\/10.1186\/s12938-022-01062-y.","journal-title":"Biomed Eng Online"},{"key":"1799_CR220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnano.2022.1055708","volume":"4","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V. Prospects of green nanotechnology for efficient management of neurodegenerative diseases. Front Nanotechnol. 2022;4:1\u20136. https:\/\/doi.org\/10.3389\/fnano.2022.1055708.","journal-title":"Front Nanotechnol"},{"issue":"8","key":"1799_CR221","doi-asserted-by":"publisher","first-page":"44","DOI":"10.7759\/cureus.44302","volume":"15","author":"C Ekhator","year":"2023","unstructured":"Ekhator C, et al. Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances. Cureus. 2023;15(8):44\u201358. https:\/\/doi.org\/10.7759\/cureus.44302.","journal-title":"Cureus"},{"issue":"3","key":"1799_CR222","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/0929867329666220328125206","volume":"30","author":"A Unnisa","year":"2022","unstructured":"Unnisa A, Greig NH, Kamal MA. Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer\u2019s Disease. Curr Med Chem. 2022;30(3):255\u201370. https:\/\/doi.org\/10.2174\/0929867329666220328125206.","journal-title":"Curr Med Chem"},{"issue":"4","key":"1799_CR223","doi-asserted-by":"publisher","first-page":"042401","DOI":"10.1149\/2754-2726\/ac973e","volume":"1","author":"A Gautam","year":"2022","unstructured":"Gautam A. Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects. ECS Sensors Plus. 2022;1(4):042401. https:\/\/doi.org\/10.1149\/2754-2726\/ac973e.","journal-title":"ECS Sensors Plus"},{"issue":"9","key":"1799_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/polym15092196","volume":"15","author":"L Duan","year":"2023","unstructured":"Duan L, et al. Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases. Polymers (Basel). 2023;15(9):1\u201319. https:\/\/doi.org\/10.3390\/polym15092196.","journal-title":"Polymers (Basel)"},{"issue":"8","key":"1799_CR225","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/10837450.2021.1950186","volume":"26","author":"R Lombardo","year":"2021","unstructured":"Lombardo R, Musumeci T, Carbone C, Pignatello R. Nanotechnologies for intranasal drug delivery: an update of literature. Pharm Dev Technol. 2021;26(8):824\u201345. https:\/\/doi.org\/10.1080\/10837450.2021.1950186.","journal-title":"Pharm Dev Technol"},{"key":"1799_CR226","doi-asserted-by":"publisher","unstructured":"J. Ahmad et al., \u201cNovel therapeutic interventions for combating Parkinson\u2019s disease and prospects of Nose-to-Brain drug delivery,\u201d. Biochem Pharmacol 195, 2021, 114849, 2022. https:\/\/doi.org\/10.1016\/j.bcp.2021.114849.","DOI":"10.1016\/j.bcp.2021.114849"},{"issue":"8","key":"1799_CR227","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","volume":"14","author":"V Sridhar","year":"2018","unstructured":"Sridhar V, Gaud R, Bajaj A, Wairkar S. \u201cPharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease\u201d, Nanomedicine Nanotechnology. Biol Med. 2018;14(8):2609\u201318. https:\/\/doi.org\/10.1016\/j.nano.2018.08.004.","journal-title":"Biol Med"},{"key":"1799_CR228","doi-asserted-by":"publisher","first-page":"106111","DOI":"10.1016\/j.jddst.2024.106111","volume":"100","author":"S Kakulade","year":"2024","unstructured":"Kakulade S, Kulkarni D, Moravkar K, Zambad S, Tekade A, Chalikwar S. Development, characterization and pharmacokinetic evaluation of selegiline HCl loaded cubosomal thermoreversible mucoadhesive gel for nose to brain delivery. J Drug Deliv Sci Technol. 2024;100:106111. https:\/\/doi.org\/10.1016\/j.jddst.2024.106111.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"1799_CR229","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1007\/s12274-024-6598-1","volume":"17","author":"L Tang","year":"2024","unstructured":"Tang L, et al. Nanoparticle delivery for central nervous system diseases and its clinical application. Nano Res. 2024;17(7):6305\u201322. https:\/\/doi.org\/10.1007\/s12274-024-6598-1.","journal-title":"Nano Res"},{"issue":"8","key":"1799_CR230","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/pharmaceutics16081048","volume":"16","author":"S Castellani","year":"2024","unstructured":"Castellani S, et al. Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson\u2019s Disease Treatment by Intranasal Administration. Pharmaceutics. 2024;16(8):1048. https:\/\/doi.org\/10.3390\/pharmaceutics16081048.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1799_CR231","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1871524919666181126124846","volume":"19","author":"N Mishra","year":"2018","unstructured":"Mishra N, Sharma S, Deshmukh R, Kumar A, Sharma R. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson\u2019s Disease. Cent Nerv Syst Agents Med Chem. 2018;19(1):46\u201356. https:\/\/doi.org\/10.2174\/1871524919666181126124846.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"1799_CR232","doi-asserted-by":"publisher","first-page":"100701","DOI":"10.1016\/j.mtbio.2023.100701","volume":"21","author":"SS Naser","year":"2023","unstructured":"Naser SS, et al. Posterity of nanoscience as lipid nanosystems for Alzheimer\u2019s disease regression. Mater Today Bio. 2023;21:100701. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100701.","journal-title":"Mater Today Bio"},{"issue":"1","key":"1799_CR233","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/tnsci-2022-0258","volume":"13","author":"KR Mittal","year":"2022","unstructured":"Mittal KR, et al. Nanotechnology-based drug delivery for the treatment of CNS disorders. Transl Neurosci. 2022;13(1):527\u201346. https:\/\/doi.org\/10.1515\/tnsci-2022-0258.","journal-title":"Transl Neurosci"},{"key":"1799_CR234","doi-asserted-by":"publisher","first-page":"121720","DOI":"10.1016\/j.ijpharm.2022.121720","volume":"620","author":"S Cunha","year":"2022","unstructured":"Cunha S, et al. Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. Int J Pharm. 2022;620:121720. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121720.","journal-title":"Int J Pharm"},{"issue":"4","key":"1799_CR235","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/08982104.2024.2336549","volume":"34","author":"KB Khot","year":"2024","unstructured":"Khot KB, et al. Enhancing selegiline hydrochloride efficacy: Box Behnken-optimized liposomal delivery via intranasal route for Parkinson\u2019s disease intervention. J Liposome Res. 2024;34(4):575\u201392. https:\/\/doi.org\/10.1080\/08982104.2024.2336549.","journal-title":"J Liposome Res"},{"issue":"3","key":"1799_CR236","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/jnc.15288","volume":"157","author":"JR Pinnell","year":"2021","unstructured":"Pinnell JR, Cui M, Tieu K. Exosomes in Parkinson disease. J Neurochem. 2021;157(3):413\u201328. https:\/\/doi.org\/10.1111\/jnc.15288.","journal-title":"J Neurochem"},{"issue":"3","key":"1799_CR237","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11481-019-09875-w","volume":"15","author":"F Shahjin","year":"2020","unstructured":"Shahjin F, Chand S, Yelamanchili SV. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System. J Neuroimmune Pharmacol. 2020;15(3):443\u201358. https:\/\/doi.org\/10.1007\/s11481-019-09875-w.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1799_CR238","doi-asserted-by":"publisher","unstructured":"L. Nieland, S. Mahjoum, E. Grandell, K. Breyne, and X. O. Breakefield, \u201cEngineered EVs designed to target diseases of the CNS,\u201d. J Control Release. 356, 2022, 493\u2013506, 2023, https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.009","DOI":"10.1016\/j.jconrel.2023.03.009"},{"issue":"18","key":"1799_CR239","doi-asserted-by":"publisher","first-page":"10068","DOI":"10.3390\/ijms251810068","volume":"25","author":"M Malaguarnera","year":"2024","unstructured":"Malaguarnera M, Cabrera-Pastor A. Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies. Int J Mol Sci. 2024;25(18):10068. https:\/\/doi.org\/10.3390\/ijms251810068.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1799_CR240","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.3390\/ijms25137371","volume":"25","author":"G Zanirati","year":"2024","unstructured":"Zanirati G, et al. Extracellular Vesicles: The Next Generation of Biomarkers and Treatment for Central Nervous System Diseases. Int J Mol Sci. 2024;25(13):7371. https:\/\/doi.org\/10.3390\/ijms25137371.","journal-title":"Int J Mol Sci"},{"key":"1799_CR241","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2023.1184435","volume":"15","author":"R Pan","year":"2023","unstructured":"Pan R, Chen D, Hou L, Hu R, Jiao Z. Small extracellular vesicles: a novel drug delivery system for neurodegenerative disorders. Front Aging Neurosci. 2023;15:1\u201315. https:\/\/doi.org\/10.3389\/fnagi.2023.1184435.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1799_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-022-00330-0","volume":"11","author":"X Xia","year":"2022","unstructured":"Xia X, Wang Y, Zheng JC. Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases. Transl Neurodegener. 2022;11(1):1\u201331. https:\/\/doi.org\/10.1186\/s40035-022-00330-0.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1799_CR243","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9(1):27. https:\/\/doi.org\/10.1038\/s41392-024-01735-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"1799_CR244","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","volume":"20","author":"A M\u00f6ller","year":"2020","unstructured":"M\u00f6ller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20(12):697\u2013709. https:\/\/doi.org\/10.1038\/s41568-020-00299-w.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1799_CR245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10091327","volume":"10","author":"L Leggio","year":"2020","unstructured":"Leggio L, et al. Extracellular vesicles as nanotherapeutics for Parkinson\u2019s disease. Biomolecules. 2020;10(9):1\u201335. https:\/\/doi.org\/10.3390\/biom10091327.","journal-title":"Biomolecules"},{"key":"1799_CR246","doi-asserted-by":"publisher","unstructured":"M. R. Teixeira, A. L. Alievi, V. R. da Costa, J. R. Dias Pinto, and R. P. Araldi, \u201cTherapeutic potential of extracellular vesicles in Parkinson\u2019s disease,\u201d. Explor Neurosci. 2024, 106\u2013122, 2023, https:\/\/doi.org\/10.37349\/en.2023.00016","DOI":"10.37349\/en.2023.00016"},{"issue":"2020","key":"1799_CR247","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","volume":"159","author":"OM Elsharkasy","year":"2020","unstructured":"Elsharkasy OM, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020;159(2020):332\u201343. https:\/\/doi.org\/10.1016\/j.addr.2020.04.004.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"1799_CR248","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41419-020-2473-5","volume":"11","author":"HX Chen","year":"2020","unstructured":"Chen HX, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson\u2019s disease model by inducing autophagy. Cell Death Dis. 2020;11(4):288. https:\/\/doi.org\/10.1038\/s41419-020-2473-5.","journal-title":"Cell Death Dis"},{"key":"1799_CR249","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.JCONREL.2018.08.035","volume":"287","author":"M Qu","year":"2018","unstructured":"Qu M, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease. J Control Release. 2018;287:156\u201366. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.08.035.","journal-title":"J Control. Release"},{"key":"1799_CR250","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","volume":"262","author":"D Rufino-Ramos","year":"2017","unstructured":"Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, Pereira de Almeida L. Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. J Control Release. 2017;262:247\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.001.","journal-title":"J Control Release"},{"issue":"7","key":"1799_CR251","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1007\/s12035-018-1419-8","volume":"56","author":"K Jamebozorgi","year":"2019","unstructured":"Jamebozorgi K, et al. Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Mol Neurobiol. 2019;56(7):4799\u2013811. https:\/\/doi.org\/10.1007\/s12035-018-1419-8.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1799_CR252","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-023-02250-1","volume":"21","author":"DE Nayab","year":"2023","unstructured":"Nayab DE, et al. Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective. J Nanobiotechnology. 2023;21(1):1\u201329. https:\/\/doi.org\/10.1186\/s12951-023-02250-1.","journal-title":"J Nanobiotechnology"},{"key":"1799_CR253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2021.107873","volume":"227","author":"A Bortolozzi","year":"2021","unstructured":"Bortolozzi A, Manashirov S, Chen A, Artigas F. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson\u2019s disease. Pharmacol Ther. 2021;227:1\u201382. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107873.","journal-title":"Pharmacol Ther"},{"key":"1799_CR254","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.mtadv.2022.100240","volume":"14","author":"RA Meyer","year":"2022","unstructured":"Meyer RA, Neshat SY, Green JJ, Santos JL, Tuesca AD. Targeting strategies for mRNA delivery. Mater Today Adv. 2022;14:100240. https:\/\/doi.org\/10.1016\/j.mtadv.2022.100240.","journal-title":"Mater Today Adv"},{"key":"1799_CR255","doi-asserted-by":"publisher","first-page":"116691","DOI":"10.1016\/j.biopha.2024.116691","volume":"175","author":"N Naimi","year":"2024","unstructured":"Naimi N, Seyedmirzaei H, Hassannejad Z, Soltani Khaboushan A. Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders. Biomed Pharmacother. 2024;175:116691. https:\/\/doi.org\/10.1016\/j.biopha.2024.116691.","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"1799_CR256","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/biot.201100054","volume":"6","author":"JC Burnett","year":"2011","unstructured":"Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA\/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6(9):1130\u201346. https:\/\/doi.org\/10.1002\/biot.201100054.","journal-title":"Biotechnol J"},{"issue":"9","key":"1799_CR257","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JKW Lam","year":"2015","unstructured":"Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4(9):e252. https:\/\/doi.org\/10.1038\/mtna.2015.23.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1799_CR258","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2013.12.026","volume":"176","author":"H Ragelle","year":"2014","unstructured":"Ragelle H, et al. Chitosan nanoparticles for siRNA delivery: Optimizing formulation to increase stability and efficiency. J Control Release. 2014;176(1):54\u201363. https:\/\/doi.org\/10.1016\/j.jconrel.2013.12.026.","journal-title":"J Control Release"},{"issue":"1","key":"1799_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-04461-4","volume":"21","author":"Y Geng","year":"2023","unstructured":"Geng Y, et al. FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson\u2019s disease via m6A-dependent regulation of ATM mRNA. J Transl Med. 2023;21(1):1\u201315. https:\/\/doi.org\/10.1186\/s12967-023-04461-4.","journal-title":"J Transl Med"},{"key":"1799_CR260","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"C Helmschrodt","year":"2017","unstructured":"Helmschrodt C, et al. Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce \u03b1-Synuclein Expression in a Model of Parkinson\u2019s Disease. Mol Ther Nucleic Acids. 2017;9:57\u201368. https:\/\/doi.org\/10.1016\/j.omtn.2017.08.013.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1799_CR261","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jconrel.2015.11.017","volume":"220","author":"H Zhu","year":"2015","unstructured":"Zhu H, Zhang S, Ling Y, Meng G, Yang Y, Zhang W. PH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery. J Control Release. 2015;220:529\u201344. https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.017.","journal-title":"J. Control. Release"},{"issue":"9","key":"1799_CR262","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1021\/nn3030223","volume":"6","author":"J Conde","year":"2012","unstructured":"Conde J, et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano. 2012;6(9):8316\u201324. https:\/\/doi.org\/10.1021\/nn3030223.","journal-title":"ACS Nano"},{"key":"1799_CR263","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-114","volume":"14","author":"J Chen","year":"2014","unstructured":"Chen J, et al. Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer. 2014;14:1. https:\/\/doi.org\/10.1186\/1471-2407-14-114.","journal-title":"BMC Cancer"},{"key":"1799_CR264","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.arr.2015.03.001","volume":"21","author":"MJ Gomes","year":"2015","unstructured":"Gomes MJ, Martins S, Sarmento B. SiRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery. Ageing Res Rev. 2015;21:43\u201354. https:\/\/doi.org\/10.1016\/j.arr.2015.03.001.","journal-title":"Ageing Res Rev"},{"key":"1799_CR265","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","volume":"87","author":"G Ozcan","year":"2015","unstructured":"Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108\u201319. https:\/\/doi.org\/10.1016\/j.addr.2015.01.007.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1799_CR266","first-page":"187","volume":"85","author":"K Gavrilov","year":"2012","unstructured":"Gavrilov K, Saltzman WM. Therapeutic siRNA: Principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187\u2013200.","journal-title":"Yale J Biol Med"},{"issue":"2012","key":"1799_CR267","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.2147\/IJN.S23696","volume":"7","author":"E Miele","year":"2012","unstructured":"Miele E, et al. Nanoparticle-based delivery of small interfering RNA: Challenges for cancer therapy. Int J Nanomedicine. 2012;7(2012):3637\u201357. https:\/\/doi.org\/10.2147\/IJN.S23696.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"1799_CR268","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s13311-015-0344-z","volume":"12","author":"LV Reddy","year":"2015","unstructured":"Reddy LV, Miller TM. RNA-targeted Therapeutics for ALS. Neurotherapeutics. 2015;12(2):424\u20137. https:\/\/doi.org\/10.1007\/s13311-015-0344-z.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1799_CR269","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12035-021-02555-y","volume":"59","author":"DGT Parambi","year":"2022","unstructured":"Parambi DGT, et al. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol. 2022;59(1):191\u2013233. https:\/\/doi.org\/10.1007\/s12035-021-02555-y.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1799_CR270","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"TM Axelsen","year":"2018","unstructured":"Axelsen TM, Woldbye DPD. Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis. 2018;8(2):195\u2013215. https:\/\/doi.org\/10.3233\/JPD-181331.","journal-title":"J Parkinsons Dis"},{"key":"1799_CR271","doi-asserted-by":"publisher","first-page":"104513","DOI":"10.1016\/J.NBD.2019.104513","volume":"130","author":"KL Jackson","year":"2019","unstructured":"Jackson KL, et al. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease. Neurobiol Dis. 2019;130:104513. https:\/\/doi.org\/10.1016\/J.NBD.2019.104513.","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"1799_CR272","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/J.YMTHE.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito G, et al. AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. Mol Ther. 2017;25(12):2727\u201342. https:\/\/doi.org\/10.1016\/J.YMTHE.2017.08.004.","journal-title":"Mol Ther"},{"issue":"s2","key":"1799_CR273","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/jpd-212739","volume":"11","author":"A Abeliovich","year":"2021","unstructured":"Abeliovich A, Hefti F, Sevigny J. Gene Therapy for Parkinson\u2019s Disease Associated with GBA1 Mutations. J Parkinsons Dis. 2021;11(s2):S183\u20138. https:\/\/doi.org\/10.3233\/jpd-212739.","journal-title":"J Parkinsons Dis"},{"issue":"18","key":"1799_CR274","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMOA1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMOA1706198.","journal-title":"N Engl J Med"},{"issue":"5","key":"1799_CR275","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ANA.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol. 2019;85(5):704\u201314. https:\/\/doi.org\/10.1002\/ANA.25450.","journal-title":"Ann Neurol"},{"issue":"2","key":"1799_CR276","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/BRAINSCI9020030","volume":"9","author":"EM Gatto","year":"2019","unstructured":"Gatto EM, Da Prat G, Etcheverry JL, Drelichman G, Cesarini M. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Sci. 2019;9(2):30. https:\/\/doi.org\/10.3390\/BRAINSCI9020030.","journal-title":"Brain Sci"},{"key":"1799_CR277","doi-asserted-by":"publisher","unstructured":"H. L. Ma LY, Wang L, Liang J, \u201cBrain and Behavior - 2024 - Ma - Investigating the neuroprotective potential of rAAV2\u2010PCBP1\u2010EGFP gene therapy against a 6\u2010OHDA\u2010induced model of Parkinson\u2019s disease,\u201d. Brain Behav., 202414 12. https:\/\/doi.org\/10.1002\/brb3.3376","DOI":"10.1002\/brb3.3376"},{"key":"1799_CR278","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00804-0","volume":"10","author":"AD Currie","year":"2024","unstructured":"Currie AD, Wong JK, Okun MS. \u201cA review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease.\u201d npj Park Dis. 2024;10:1. https:\/\/doi.org\/10.1038\/s41531-024-00804-0.","journal-title":"npj Park Dis"},{"issue":"1","key":"1799_CR279","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mabi.202000269","volume":"21","author":"C Gutierrez-Millan","year":"2021","unstructured":"Gutierrez-Millan C, Calvo D\u00edaz C, Lanao JM, Colino CI. Advances in Exosomes-Based Drug Delivery Systems. Macromol Biosci. 2021;21(1):577\u201394. https:\/\/doi.org\/10.1002\/mabi.202000269.","journal-title":"Macromol Biosci"},{"issue":"15","key":"1799_CR280","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21155241","volume":"21","author":"M D\u2019angelo","year":"2020","unstructured":"D\u2019angelo M, Cimini A, Castelli V. Insights into the effects of mesenchymal stem cell-derived secretome in Parkinson\u2019s disease. Int J Mol Sci. 2020;21(15):1\u201314. https:\/\/doi.org\/10.3390\/ijms21155241.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1799_CR281","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.molpharmaceut.0c00195","volume":"17","author":"S Luo","year":"2020","unstructured":"Luo S, Du L, Cui Y. Potential Therapeutic Applications and Developments of Exosomes in Parkinson\u2019s Disease. Mol Pharm. 2020;17(5):1447\u201357. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00195.","journal-title":"Mol Pharm"},{"issue":"12","key":"1799_CR282","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/J.YMTHE.2019.08.010","volume":"27","author":"M Izco","year":"2019","unstructured":"Izco M, et al. Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Mol Ther. 2019;27(12):2111\u201322. https:\/\/doi.org\/10.1016\/J.YMTHE.2019.08.010.","journal-title":"Mol Ther"},{"key":"1799_CR283","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/J.JCONREL.2018.03.019","volume":"277","author":"M Qu","year":"2018","unstructured":"Qu M, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease. J Control Release. 2018;277:173\u201382. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.03.019.","journal-title":"J Control Release"},{"key":"1799_CR284","doi-asserted-by":"publisher","first-page":"119326","DOI":"10.1016\/j.lfs.2021.119326","volume":"274","author":"DP Anthony","year":"2021","unstructured":"Anthony DP, Hegde M, Shetty SS, Rafic T, Mutalik S, Rao BSS. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. Life Sci. 2021;274:119326. https:\/\/doi.org\/10.1016\/j.lfs.2021.119326.","journal-title":"Life Sci"},{"issue":"30","key":"1799_CR285","doi-asserted-by":"publisher","first-page":"10919","DOI":"10.1039\/C7NR00305F","volume":"9","author":"S Prabhu","year":"2017","unstructured":"Prabhu S, et al. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin. Nanoscale. 2017;9(30):10919\u201332. https:\/\/doi.org\/10.1039\/C7NR00305F.","journal-title":"Nanoscale"},{"issue":"1","key":"1799_CR286","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13568-019-0869-3","volume":"9","author":"X Ji","year":"2019","unstructured":"Ji X, Wang H, Chen Y, Zhou J, Liu Y. Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood\u2013brain barrier and target glioma. AMB Express. 2019;9(1):165. https:\/\/doi.org\/10.1186\/s13568-019-0869-3.","journal-title":"AMB Express"},{"issue":"10","key":"1799_CR287","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1021\/ACS.BIOCONJCHEM.9B00505","volume":"30","author":"A Gothwal","year":"2019","unstructured":"Gothwal A, et al. Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer\u2019s Disease in Mice. Bioconjug Chem. 2019;30(10):2573\u201383. https:\/\/doi.org\/10.1021\/ACS.BIOCONJCHEM.9B00505.","journal-title":"Bioconjug Chem"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01799-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:22:10Z","timestamp":1770304930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01799-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":287,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01799-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"13 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflict of interest and disclosures are associated with the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author declares that they have provided their consent to publish this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial or other interests that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}